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Summary 
Autism spectrum disorders (ASD) are a group of devastating 
neurodevelopmental syndromes that affect up to 1 in 68 children. Despite advances in 
the identification of ASD risk genes, the mechanisms underlying ASD remain unknown. 
Homozygous loss-of-function mutations in Contactin Associated Protein-like 2 
(CNTNAP2) are strongly linked to ASD. Here we investigate the function of Cntnap2 
and undertake pharmacological screens to identify phenotypic suppressors. We find 
that zebrafish cntnap2 mutants display GABAergic deficits particularly in the forebrain 
and sensitivity to drug-induced seizures. High-throughput behavioral profiling identifies 
nighttime hyperactivity in cntnap2 mutants, while pharmacological testing reveals 
dysregulation of GABAergic and glutamatergic systems. Finally, we find that estrogen 
receptor agonists elicit a behavioral fingerprint anti-correlative to that of cntnap2 
mutants and show that the phytoestrogen biochanin A specifically reverses the mutant 
behavioral phenotype. These results identify estrogenic compounds as phenotypic 
suppressors and illuminate novel pharmacological pathways with relevance to autism.  
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Introduction 
Autism spectrum disorders (ASD) are a group of neurodevelopmental syndromes 
characterized by deficits in social interaction and communication as well as repetitive 
behaviors and restricted interests (American Psychiatric Association, 2013). Gene 
discovery in ASD has accelerated dramatically (De Rubeis et al., 2014; Iossifov et al., 
2014; Sanders et al., 2015), providing a launching point for the illumination of relevant 
biological pathways (Parikshak et al., 2013; Willsey et al., 2013). Contactin Associated 
Protein-like 2 (CNTNAP2) is one of the first genes strongly linked to autism and epilepsy 
in consanguineous families (Strauss et al., 2006). This gene encodes a cell adhesion 
molecule of the neurexin family that localizes voltage-gated potassium channels at the 
juxtaparanodal region of myelinated axons (Poliak et al., 2003). Loss of CNTNAP2 
function in mice leads to abnormal neuronal migration, reduced GABAergic neurons, 
spontaneous seizures, hyperactivity, social deficits, and increased repetitive behaviors 
(Penagarikano et al., 2011). However, the function of CNTNAP2 in the central nervous 
system and the consequences of its loss for ASD pathology are less well understood.  
At present, our ability to advance rapidly from the identification of risk genes to 
the discovery of biological mechanisms and pharmacological suppressors remains 
limited. The zebrafish is a model vertebrate system well-suited for conducting small 
molecule screens to uncover modulators of signaling pathways (Ablain and Zon, 2013; 
Kokel and Peterson, 2011; Rihel and Schier, 2012). Quantitative behavioral profiling 
provides a high-throughput approach to characterize psychoactive molecules based on 
the behavioral readout of their effects in zebrafish larvae (Rihel et al., 2010). Here we 
investigate the consequences of the loss of Cntnap2 in zebrafish and utilize quantitative 
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behavioral profiling as a platform to conduct rational pharmacological screens to identify 
phenotypic suppressors and novel pathways with relevance to autism. 
 
Results 
cntnap2 Mutants Display GABAergic Deficits 
Zebrafish have two cntnap2 paralogs that are expressed broadly in the 
developing central nervous system (CNS), with higher expression in the telencephalon 
(Figure S1A-C). Cntnap2a and Cntnap2b proteins show 71% and 65% identity to the 
human protein, respectively, and contain the same functional domains (Figure 1A). To 
characterize their function, we generated two loss-of-function mutations in each paralog 
using zinc finger nucleases and crossed fish carrying these alleles to generate double 
mutant fish (cntnap2aΔ121/Δ121cntnap2b31i/31i and cntnap2aΔ25/Δ25cntnap2bΔ7/Δ7) (Figure 
S1D-F), referred to hereafter as cntnap2ab mutants. Each mutation causes a premature 
stop codon within the discoidin domain and results in loss of protein expression (Figures 
1A and 1B), such that double mutants represent a loss of Cntnap2 function. 
It has been proposed that an imbalance in excitatory and inhibitory signaling in 
the CNS is a mechanism underlying ASD and epilepsy (Rubenstein and Merzenich, 
2003). To test if this is occurring in cntnap2ab mutants, we analyzed inhibitory and 
excitatory neuronal populations in wild-type and cntnap2ab mutants during early brain 
development, using transgenic lines that label GABAergic neurons and precursors 
(Tg(dlx6a-1.4kbdlx5a/dlx6a:GFP)) and glutamatergic neurons (Tg(vglut:DsRed)) 
(Ghanem et al., 2003; Kinkhabwala et al., 2011; Yu et al., 2011; Zerucha et al., 2000). 
We observed a significant decrease in GABAergic cells in cntnap2ab mutants at 4 days 
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post fertilization (dpf) (Figures 1C-F and 1C’-F’; and Figures S2A-H and S2A’-H’) in the 
forebrain and cerebellum (Figure S2I-J). In particular, there were an average of 34% 
fewer GABAergic neurons in the forebrain of cntnap2ab mutants compared to wild-type 
fish at 4 dpf (Figure 1G, p=3.08x10-7, one-way ANOVA). The decreased number of 
GABAergic cells in the dorsal telencephalon (pallium) at this stage is consistent with a 
failure in the migration of these cells from the ventral telencephalon (subpallium), as has 
been reported in Cntnap2 mutant mice (Penagarikano et al., 2011). In contrast, there 
were no significant regional deficits in glutamatergic neurons (Figure S2A-H, S2A’-H’ 
and S2K).  
Although there were no gross morphological abnormalities in the structure of the 
axon scaffold in cntnap2ab mutants between 48 hpf and 5 dpf (Figures S1G-I and S1G’-
I’), mutant head size is significantly smaller (Table S1, Figures S1N-R and S1N’-Q’). In 
addition, we did not observe gross differences in markers of apoptosis (TUNEL staining) 
at 28 hpf or proliferation (phospho-histone H3) at 48 hpf (Figures S2R-S and S2R’-S’). 
However, deficits in GABAergic neurons and transient delays in commissure formation 
are evident in the forebrain of mutants at 28 hpf (Figures S1J-M and S1J’-K’), indicating 
additional early roles for Cntnap2 in brain development. Together, these data indicate 
loss of Cntnap2 results in a deficit of inhibitory neurons, particularly in the forebrain. 
 
Increased Seizure Susceptibility in cntnap2 Mutants 
 Loss of inhibitory neurons can increase susceptibility to seizures (Cobos et al., 
2005). To determine the effect of loss of Cntnap2 on seizure susceptibility in zebrafish, 
we treated wild-type and mutant larvae with pentylenetetrazol (PTZ), a GABA-A 
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receptor antagonist that induces seizures in rodents and zebrafish (Baraban et al., 
2005; Watanabe et al., 2010). cntnap2ab mutants display increased sensitivity to PTZ-
induced seizures (Figure 1H and Figure S3A-F). Drug-induced seizures appear as 
robust increases in activity and rapid, burst-like and circling movements, followed by 
periods of inactivity (Baraban et al., 2005). Homozygous double mutants display 
significantly more activity in response to PTZ than background-matched wild-type larvae 
and all intermediate genotypes (Figure S4B, p=0.0013, two-way ANOVA, genotype x 
dose interaction, n=268). These results are consistent with increased seizures 
associated with CNTNAP2 mutations in humans and mice (Penagarikano et al., 2011; 
Strauss et al., 2006). Consequently, increased sensitivity to PTZ provides further 
evidence for GABAergic deficits in cntnap2ab mutants. 
 
cntnap2 Mutants Show Nighttime Hyperactivity 
We next adapted a blinded, high-throughput assay to quantify a series of 
behavioral parameters, including rest-wake cycle behaviors over multiple days (Figure 
2A) (Prober et al., 2006; Rihel et al., 2010). Quantitative profiling revealed that 
cntnap2ab mutants display significantly greater nighttime activity compared to wild-type 
siblings between 4 and 7 dpf (Figures 2B and 2C and Figure S3G, p=0.00012, one-way 
ANOVA, n=838). This phenotype was independently observed in cntnap2ab mutants 
harboring different alleles (Figure S3H, p=0.0198, n=187). In contrast, analysis of other 
rest-wake parameters (e.g. total day and night rest, sleep latency, etc.) (Table S2), as 
well as acoustic startle, habituation, and optokinetic response (Table S3) were not 
significantly affected, further highlighting the specificity of the nighttime hyperactivity 
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phenotype. Combined, these results indicate that loss of Cntnap2 selectively causes 
nighttime hyperactivity, consistent with GABAergic deficits leading to an imbalance of 
excitatory and inhibitory signaling in mutant fish. 
 
Differential Responses to Psychoactive Agents in cntnap2 Mutants 
Collectively, the day-night, rest-wake cycle parameters of cntnap2ab mutants 
represent a genotypic behavioral fingerprint with a specific nighttime hyperactivity 
signature. To identify molecular pathways that are dysregulated in the absence of 
Cntnap2 function, we searched for drugs that phenocopy the mutant behavioral profile. 
To this end, we compared the cntnap2ab mutant behavioral fingerprint to a dataset of 
the behavioral profiles of wild-type larvae exposed to 550 psychoactive compounds 
(Rihel et al., 2010). This allows for an unbiased comparison of the different genetic and 
pharmacological conditions by cluster analysis (Rihel et al., 2010) (Figure 2D), and 
resulted in the identification of small molecules that strongly correlate with the mutant 
behavioral profile (Figure 2E). Next, we identified the top 14 drugs that anti-correlate, or 
generate the opposite phenotype of the mutant behavioral profile (Figure S4H). We 
reasoned that drugs that induce differential effects in wild-type and mutant larvae might 
indicate pathways that are dysregulated due to loss of Cntnap2. To test this, we 
exposed wild-type and cntnap2aΔ121/Δ121cntnap2b31i/31i larvae to a group of compounds 
from 4 to 7 dpf (Figure 3A) that were selected based on the following criteria: (1) 
correlating; (2) anti-correlating; (3) GABA-A receptor agonists, based on the structural 
GABAergic deficits; and (4) risperidone, because it is the first FDA-approved treatment 
for irritability and aggressive behavior in ASD (McCracken et al., 2002). 
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 Three lines of evidence indicate that both glutamatergic and GABAergic 
pathways are dysregulated in cntnap2ab mutants. First, we found that both GABA- and 
NMDA-receptor antagonists are significantly enriched among drugs that strongly 
correlate with the mutant phenotype (Figures 3D and 3E, p=0.031 and p=0.034, 
respectively, Kolmogorov-Smirnov). These findings are consistent with the behavioral 
profile of cntnap2ab mutants, given that NMDA receptor antagonists induce nighttime 
hyperactivity in wild-type larvae, and the increased sensitivity of mutants to the GABA-A 
receptor antagonist, PTZ. Second, cntnap2ab mutants are more sensitive to arousal by 
NMDA receptor antagonists across a range of doses (Figure 3B), suggesting 
attenuation of glutamatergic signaling.  
Third, we found that GABA receptor agonists, such as zolpidem, induce 
differential behavioral effects in cntnap2ab mutants compared to wild-type larvae 
(Figures 3C and 3F-H). For this analysis, we performed hierarchical clustering and 
principal component analysis (PCA) to quantify differential mutant responses compared 
to wild-type across 18 rest-wake activity parameters (Rihel et al., 2010). Specifically, we 
calculated the Euclidean distance between the mutant + drug and wild-type + drug 
behavioral profiles, representing the difference between the mutant and wild-type 
responses to each drug (Figure 3H and Figure S4A-F; see Supplemental Experimental 
Procedures for details). Using this approach, we found that the GABA receptor agonists, 
zolpidem and (±)-baclofen, produce the strongest differential responses of the drugs 
tested (Figure 3H), suggesting perturbation of GABAergic signaling pathways in 
mutants. Taken together, our quantitative behavioral profiling reveals dysfunction in 
glutamatergic as well as GABAergic pathways due to loss of Cntnap2. 
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Estrogens Reverse the Behavioral Phenotype of cntnap2ab Mutants 
 Next, we searched for small molecules that suppress the mutant phenotype of 
nighttime hyperactivity. We reasoned that such compounds might elicit a behavioral 
fingerprint in wild-type opposite to that of mutant larvae. To this end, we compared the 
dataset of the behavioral profiles of wild-type larvae exposed to a total of 550 small 
molecules (Rihel et al., 2010) with the behavioral profile of cntnap2ab mutants to 
determine which anti-correlate with the cntnap2ab mutant behavioral fingerprint (Figure 
S4H). We found that estrogenic compounds are significantly enriched in the top ranks of 
the anti-correlating dataset (Figure 4A, p=0.0003 by random permutation). Specifically, 
four of the top ten anti-correlating drugs have known estrogenic activity. Based on these 
results, we hypothesized that such drugs might be able to rescue the mutant phenotype. 
To test this hypothesis, we analyzed the effects of estrogenic compounds and other 
selected molecules in wild-type and mutant larvae using quantitative behavioral profiling 
and PCA analysis (Figure 3A; see Supplemental Experimental Procedures for details). 
Behavioral rescue was defined as the shortest Euclidean distance between the mutant 
+ drug and wild type + no drug behavioral profiles (Figure 4D).  
We found that biochanin A, a plant-derived estrogen, and β-estradiol 17-
cypionate most strongly reverse the mutant behavioral phenotype (Figures 4B-D and 
Figure S4G). Indeed, the behavioral response of cntnap2ab larvae treated with 
biochanin A (0.1 µM) from 4 to 7 dpf most strongly correlates with the wild-type 
phenotype, decreasing nighttime activity with little effect on other measures of rest and 
activity (Figures 4B and 4C). In contrast, risperidone (0.001 µM) reverses nighttime 
hyperactivity, but alters other rest-wake cycle parameters, indicating that it elicits a less 
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specific phenotypic rescue than biochanin A (Figures 4C and 4E-F). In addition, we 
found that early exposure to biochanin A does not reverse the GABAergic deficits 
(Figure S4M) or drug-induced seizures (Figure S4K), and that chronic exposure 
followed by washout does not rescue nighttime hyperactivity (Figure S4L), providing 
evidence for an acute mechanism of action. Consistent with estrogenic activity, we 
found that biochanin A (10 µM) significantly activates the expression of estrogen 
response genes in zebrafish larvae (Figure S4N). However, the rescue dose (1 µM) 
shows only a weak effect on target genes, suggesting that the behavioral rescue might 
occur independently of the robust transcriptional activation of estrogen target genes. 
Moreover, we found that biochanin A (0.1-1 µM) leads to selective suppression of 
nighttime activity at 5 dpf and no change in daytime activity in background-matched 
larvae (Figures 4G and 4H), indicating its effects are not due to background effects or 
generalized sedation. Furthermore, β-estradiol (1 µM) is also able to rescue nighttime 
hyperactivity in cntnap2ab mutants (Figure S4J). Together, these results provide 
evidence that biochanin A and β-estradiol acutely suppress a specific behavioral 
phenotype in a genetic loss-of-function model of an ASD risk gene. 
 
Discussion 
This study represents the first characterization of zebrafish mutants of an ASD 
risk gene using quantitative behavioral profiling to identify biological pathways with 
relevance to ASD. We demonstrate that zebrafish cntnap2ab mutants display 
reductions in GABAergic neurons, increased sensitivity to drug-induced seizures, and 
nighttime hyperactivity. Further, our pharmacological data provide evidence for 
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dysregulation of both GABAergic and glutamatergic signaling in mutants. Altered NMDA 
signaling has been shown to cause GABAergic deficits, particularly in parvalbumin-
positive (PV+) interneurons, and has been proposed as a mechanism underlying 
neuropsychiatric disorders (Billingslea et al., 2014; Keilhoff et al., 2004; Kittelberger et 
al., 2012; Saunders et al., 2013). Interestingly, mouse Cntnap2 knockouts display 
GABAergic deficits, most prominently affecting PV+ interneurons (Penagarikano et al., 
2011). Further studies are required to determine if PV+ subpopulations are altered in 
cntnap2ab mutants, but our study highlights that GABAergic deficits are likely to occur 
in concert with alterations in NMDA circuits, not previously associated with Cntnap2.  
Next, our results uncover the ability of estrogens to rescue the cntnap2 mutant 
behavioral phenotype, suggesting that these compounds serve as modifiers of neural 
circuits disrupted in mutants. Indeed, estrogens can signal to multiple downstream 
pathways, including transcriptional activation of estrogen response genes, regulation of 
other transcription factors, and rapid activation of intracellular signaling pathways 
(Marino et al., 2006). The extent to which estrogens alter one or more downstream 
intracellular signaling pathways remains to be determined, but our findings suggest that 
the rescue activity likely involves an acute mechanism other than robust activation of 
estrogen target genes. For example, estrogens have been shown to affect 
glutamatergic signaling. Estradiol increases dendritic spine density and long-term 
potentiation via an NR2B-dependent mechanism that can be blocked by exposure to 
NMDA antagonists, such as MK-801 (Smith and McMahon, 2006; Smith et al., 2009; 
Snyder et al., 2011). Therefore, estrogens may be acting upstream of the identified 
NMDA and GABA deficits. While there is growing interest in the effects of sex hormones 
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on brain development and ASD risk, given the 4:1 male:female ratio of classical autism 
(Baron-Cohen et al., 2011; Schaafsma and Pfaff, 2014), further investigations are 
required to determine whether such a mechanism might contribute to the observed 
female protective effect suggested by recent human genetics studies of ASD 
(Jacquemont et al., 2014). 
Taken together, as the list of reliable ASD risk genes continues to expand 
rapidly, there is a growing need for biologically relevant systems to advance from gene 
discovery to pharmacological screens. Here, we demonstrate that quantitative 
behavioral profiling of zebrafish cntnap2ab mutants can be used as a novel platform for 
the prediction and in vivo screening of compounds to identify suppressors of a 
behavioral phenotype resulting from loss of an ASD risk gene. Future testing in a 
mammalian system is a critical next step. Moreover, the study of zebrafish mutants of 
the ASD risk gene, CNTNAP2, and its differential responses to psychoactive agents 
reveals the strength of this approach to identify molecular mechanisms and potential 
pharmacological candidates for further evaluation. 
 
Experimental Procedures 
 
Mutations in zebrafish cntnap2a and cntnap2b were generated by targeted gene 
disruption using zinc finger nucleases. The cntnap2aΔ121/Δ121cntnap2b31i/31i and 
cntnap2aΔ25/Δ25cntnap2bΔ7/Δ7 lines were generated by incrossing double homozygotes, 
which are viable and fertile. Tg(dlx6a-1.4kbdlx5a/dlx6a:GFP) (Ghanem et al., 2003; 
Zerucha et al., 2000) were obtained from the laboratory of Marc Ekker and 
Tg(vglut:DsRed) (Kinkhabwala et al., 2011) from the laboratory of Joseph Fetcho. 
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Homozygous double mutants of the cntnap2aΔ121/Δ121cntnap2b31i/31i genotype were 
crossed to these transgenic lines. Animal experiments were conducted in accordance 
with IACUC regulatory standards at Yale University and project licence 70/7612, issued 
to JR under the UK Animals (Scientific Procedures) Act 1986. 
The locomotor activity assay was conducted using a custom-modified Zebrabox 
(Viewpoint, LifeSciences) and correlation analysis was performed in Matlab (R2014a; 
The Mathworks, Inc.), as previously described (Rihel et al., 2010). Each compound 
(Figure 3A) was tested on 10-12 cntnap2aΔ121/Δ121cntnap2b31i/31i or wild-type larvae, with 
10-12 control larvae per 96-well plate. Hierarchical clustering was conducted in Matlab 
(R2014a), with the statistics and bioinformatics toolboxes. PCA was performed as in 
(Woods et al., 2014). 
 
Supplemental Information 
Supplemental Information includes Supplemental Experimental Procedures, four figures, 
and three tables. 
 
 
Author Contributions 
E.J.H., M.W.S., and A.J.G. designed the project. E.J.H. generated and performed 
molecular biological and phenotypic characterization of cntnap2ab mutants. E.J.H. and 
K.J.T. performed immunohistochemistry. J.M.F. assisted in genotyping, zebrafish 
husbandry, and in situ hybridizations. D.C. developed methods for generating and 
screening zebrafish mutants using zinc finger nucleases. R.A.J. and M. Granato 
conducted and analyzed startle and habituation assays. F.K. and H.B. conducted and 
 14 
analyzed optokinetic response assays. B.R.B. provided in situ probes and discussions 
of phenotypes in cntnap2a morphants. E.J.H. and M.J.F.B. analyzed forebrain 
commissure formation. E.J.H., S.I., K.J.T. and S.W.W. analyzed central nervous system 
structure and GABAergic deficits. E.J.H., M. Ghosh, and J.R. designed and performed 
rest-wake behavioral tracking, pentylenetetrazol assays, and pharmacological screening 
experiments. J.R. designed and performed correlation analyses and PCA for 
pharmacological screens. E.J.H. wrote the manuscript with input from S.W.W., J.R., 
M.W.S., and A.J.G. 
 
Acknowledgements 
We thank J. Fetcho and M. Ekker for transgenic fish lines; B. Bill, D. Geschwind, P. 
Panula, and G. Wright for in situ probes; D. Geschwind for discussions and sharing of 
unpublished data; P. De Camilli, J. Leckman, and N. Sestan for discussions; M. Lee and 
V. Yartseva for discussions and manuscript editing; K. Divito, J. M. Fernandez, and S. 
Lau for serving as blinded raters. Supported by NIH grants K08MH096176 (E.J.H.), 
CTSA UL1TR000142 (E.J.H.), T32MH018268 (E.J.H.), R21 HD073768 (A.J.G.), R01 
HD074078 (A.J.G.), R01 GM081602 (A.J.G.), RC2MH089956 (A.J.G., M.W.S.), 
K99HD071968 (D.C.), MH092257 and MH109498 (M. Granato), Overlook International 
Foundation (M.W.S.), American Academy of Child and Adolescent Psychiatry Junior 
Investigator Award (E.J.H.), European Research Council Starting Grant (J.R.), UCL 
Excellence Fellowship (J.R.), and BBSRC, EU and Wellcome Trust grants (S.W.W.). 
 
 
 15 
References 
Ablain, J., and Zon, L.I. (2013). Of fish and men: using zebrafish to fight human 
diseases. Trends in Cell Biology 23, 584-586. 
 
American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental 
Disorders (5th ed.) (Arlington, VA: American Psychiatric Publishing). 
 
Baraban, S.C., Taylor, M.R., Castro, P.A., and Baier, H. (2005). Pentylenetetrazole 
induced changes in zebrafish behavior, neural activity and c-fos expression. 
Neuroscience 131, 759-768. 
 
Baron-Cohen, S., Lombardo, M.V., Auyeung, B., Ashwin, E., Chakrabarti, B., and 
Knickmeyer, R. (2011). Why are autism spectrum conditions more prevalent in males? 
PLoS Biology 9, e1001081. 
 
Billingslea, E.N., Tatard-Leitman, V.M., Anguiano, J., Jutzeler, C.R., Suh, J., Saunders, 
J.A., Morita, S., Featherstone, R.E., Ortinski, P.I., Gandal, M.J., et al. (2014). 
Parvalbumin cell ablation of NMDA-R1 causes increased resting network excitability 
with associated social and self-care deficits. Neuropsychopharmacology 39, 1603-1613. 
 
Cobos, I., Calcagnotto, M.E., Vilaythong, A.J., Thwin, M.T., Noebels, J.L., Baraban, 
S.C., and Rubenstein, J.L. (2005). Mice lacking Dlx1 show subtype-specific loss of 
interneurons, reduced inhibition and epilepsy. Nature Neuroscience 8, 1059-1068. 
 
De Rubeis, S., He, X., Goldberg, A.P., Poultney, C.S., Samocha, K., Cicek, A.E., Kou, 
Y., Liu, L., Fromer, M., Walker, S., et al. (2014). Synaptic, transcriptional and chromatin 
genes disrupted in autism. Nature 515, 209-215. 
 
Ghanem, N., Jarinova, O., Amores, A., Long, Q., Hatch, G., Park, B.K., Rubenstein, 
J.L., and Ekker, M. (2003). Regulatory roles of conserved intergenic domains in 
vertebrate Dlx bigene clusters. Genome Research 13, 533-543. 
 
Iossifov, I., O'Roak, B.J., Sanders, S.J., Ronemus, M., Krumm, N., Levy, D., Stessman, 
H.A., Witherspoon, K.T., Vives, L., Patterson, K.E., et al. (2014). The contribution of de 
novo coding mutations to autism spectrum disorder. Nature 515, 216-221. 
 
Jacquemont, S., Coe, B.P., Hersch, M., Duyzend, M.H., Krumm, N., Bergmann, S., 
Beckmann, J.S., Rosenfeld, J.A., and Eichler, E.E. (2014). A higher mutational burden 
in females supports a "female protective model" in neurodevelopmental disorders. 
American Journal of Human Genetics 94, 415-425. 
 
Keilhoff, G., Becker, A., Grecksch, G., Wolf, G., and Bernstein, H.G. (2004). Repeated 
application of ketamine to rats induces changes in the hippocampal expression of 
parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human 
schizophrenia. Neuroscience 126, 591-598. 
 16 
 
Kinkhabwala, A., Riley, M., Koyama, M., Monen, J., Satou, C., Kimura, Y., Higashijima, 
S., and Fetcho, J. (2011). A structural and functional ground plan for neurons in the 
hindbrain of zebrafish. Proceedings of the National Academy of Sciences of the United 
States of America 108, 1164-1169. 
 
Kittelberger, K., Hur, E.E., Sazegar, S., Keshavan, V., and Kocsis, B. (2012). 
Comparison of the effects of acute and chronic administration of ketamine on 
hippocampal oscillations: relevance for the NMDA receptor hypofunction model of 
schizophrenia. Brain Structure & Function 217, 395-409. 
 
Kokel, D., and Peterson, R.T. (2011). Using the zebrafish photomotor response for 
psychotropic drug screening. Methods in Cell Biology 105, 517-524. 
 
Marino, M., Galluzzo, P., and Ascenzi, P. (2006). Estrogen signaling multiple pathways 
to impact gene transcription. Current Genomics 7, 497-508. 
 
McCracken, J.T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M.G., Arnold, 
L.E., Lindsay, R., Nash, P., Hollway, J., et al. (2002). Risperidone in children with 
autism and serious behavioral problems. The New England Journal of Medicine 347, 
314-321. 
 
Parikshak, N.N., Luo, R., Zhang, A., Won, H., Lowe, J.K., Chandran, V., Horvath, S., 
and Geschwind, D.H. (2013). Integrative functional genomic analyses implicate specific 
molecular pathways and circuits in autism. Cell 155, 1008-1021. 
 
Penagarikano, O., Abrahams, B.S., Herman, E.I., Winden, K.D., Gdalyahu, A., Dong, 
H., Sonnenblick, L.I., Gruver, R., Almajano, J., Bragin, A., et al. (2011). Absence of 
CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related 
deficits. Cell 147, 235-246. 
 
Poliak, S., Salomon, D., Elhanany, H., Sabanay, H., Kiernan, B., Pevny, L., Stewart, 
C.L., Xu, X., Chiu, S.Y., Shrager, P., et al. (2003). Juxtaparanodal clustering of Shaker-
like K+ channels in myelinated axons depends on Caspr2 and TAG-1. The Journal of 
Cell Biology 162, 1149-1160. 
 
Prober, D.A., Rihel, J., Onah, A.A., Sung, R.J., and Schier, A.F. (2006). Hypocretin/ 
orexin overexpression induces an insomnia-like phenotype in zebrafish. The Journal of 
Neuroscience 26, 13400-13410. 
 
Rihel, J., Prober, D.A., Arvanites, A., Lam, K., Zimmerman, S., Jang, S., Haggarty, S.J., 
Kokel, D., Rubin, L.L., Peterson, R.T., et al. (2010). Zebrafish behavioral profiling links 
drugs to biological targets and rest/wake regulation. Science 327, 348-351. 
Rihel, J., and Schier, A.F. (2012). Behavioral screening for neuroactive drugs in 
zebrafish. Developmental Neurobiology 72, 373-385. 
 
 17 
Rubenstein, J.L., and Merzenich, M.M. (2003). Model of autism: increased ratio of 
excitation/inhibition in key neural systems. Genes, Brain, and Behavior 2, 255-267. 
 
Sanders, S.J., He, X., Willsey, A.J., Ercan-Sencicek, A.G., Samocha, K.E., Cicek, A.E., 
Murtha, M.T., Bal, V.H., Bishop, S.L., Dong, S., et al. (2015). Insights into Autism 
Spectrum Disorder Genomic Architecture and Biology from 71 Risk Loci. Neuron 87, 
1215-1233. 
 
Saunders, J.A., Tatard-Leitman, V.M., Suh, J., Billingslea, E.N., Roberts, T.P., and 
Siegel, S.J. (2013). Knockout of NMDA receptors in parvalbumin interneurons recreates 
autism-like phenotypes. Autism Research 6, 69-77. 
 
Schaafsma, S.M., and Pfaff, D.W. (2014). Etiologies underlying sex differences in 
Autism Spectrum Disorders. Frontiers in Neuroendocrinology 35, 255-271. 
 
Smith, C.C., and McMahon, L.L. (2006). Estradiol-induced increase in the magnitude of 
long-term potentiation is prevented by blocking NR2B-containing receptors. The Journal 
of Neuroscience 26, 8517-8522. 
 
Smith, C.C., Vedder, L.C., and McMahon, L.L. (2009). Estradiol and the relationship 
between dendritic spines, NR2B containing NMDA receptors, and the magnitude of 
long-term potentiation at hippocampal CA3-CA1 synapses. Psychoneuroendocrinology 
34 Suppl 1, S130-142. 
 
Snyder, M.A., Cooke, B.M., and Woolley, C.S. (2011). Estradiol potentiation of NR2B-
dependent EPSCs is not due to changes in NR2B protein expression or 
phosphorylation. Hippocampus 21, 398-408. 
 
Strauss, K.A., Puffenberger, E.G., Huentelman, M.J., Gottlieb, S., Dobrin, S.E., Parod, 
J.M., Stephan, D.A., and Morton, D.H. (2006). Recessive symptomatic focal epilepsy 
and mutant contactin-associated protein-like 2. The New England Journal of Medicine 
354, 1370-1377. 
 
Watanabe, Y., Takechi, K., Fujiwara, A., and Kamei, C. (2010). Effects of antiepileptics 
on behavioral and electroencephalographic seizure induced by pentetrazol in mice. 
Journal of Pharmacological Sciences 112, 282-289. 
 
 
Willsey, A.J., Sanders, S.J., Li, M., Dong, S., Tebbenkamp, A.T., Muhle, R.A., Reilly, 
S.K., Lin, L., Fertuzinhos, S., Miller, J.A., et al. (2013). Coexpression networks implicate 
human midfetal deep cortical projection neurons in the pathogenesis of autism. Cell 
155, 997-1007. 
 
Woods, I.G., Schoppik, D., Shi, V.J., Zimmerman, S., Coleman, H.A., Greenwood, J., 
Soucy, E.R., and Schier, A.F. (2014). Neuropeptidergic signaling partitions arousal 
behaviors in zebrafish. The Journal of neuroscience 34, 3142-3160. 
 18 
 
 
Yu, M., Xi, Y., Pollack, J., Debiais-Thibaud, M., Macdonald, R.B., and Ekker, M. (2011). 
Activity of dlx5a/dlx6a regulatory elements during zebrafish GABAergic neuron 
development. International Journal of Developmental Neuroscience 29, 681-691. 
 
Zerucha, T., Stuhmer, T., Hatch, G., Park, B.K., Long, Q., Yu, G., Gambarotta, A., 
Schultz, J.R., Rubenstein, J.L., and Ekker, M. (2000). A highly conserved enhancer in 
the Dlx5/Dlx6 intergenic region is the site of cross-regulatory interactions between Dlx 
genes in the embryonic forebrain. The Journal of Neuroscience 20, 709-721. 
 
 
Figure Legends 
 
 
Figure 1. cntnap2ab mutants display GABAergic deficits.  
A. Cntnap2a and Cntnap2b proteins showing functional domains. The predicted size of 
the truncated proteins is shown. (DISC = Discoidin; LamG = Laminin G; EGF = 
Epidermal Growth Factor; TM = Transmembrane; 4.1 = 4.1 Binding Domain).  
B. Western blot analysis of Cntnap2a and Cntnap2b in cntnap2aΔ25/Δ25cntnap2bΔ7/Δ7 and 
cntnap2aΔ121/Δ121cntnap2b31i/31i fish. Protein expression in double homozygotes, single 
homozygotes, and double heterozygotes is shown.  
C-F, C’-F’. Reporter gene expression in Tg(dlx6a-1.4kbdlx5a/dlx6a:GFP) and 
Tg(vglut:DsRed) in wild-type (C-F) and cntnap2aΔ121/Δ121cntnap2b31i/31i (cntnap2ab) (C’-
F’) larvae at 4 dpf. Note the deficit in dlx5a/6a:GFP+ cells in the telencephalon 
(arrowheads). (C-D, C’-D’): lateral views. (E-F, E’-F’): ventral views. (tel, telencephalon; 
hyp, hypothalamus; OT, optic tectum.)  
G. Total number of dlx5a/6a:GFP+ cells in the forebrain of wild-type (n=13) and 
cntnap2ab mutants (n=14) (*p=3.08 x 10-7, one-way ANOVA).  
H. Average activity in response to pentylenetetrazol (PTZ) (10 mM) in the progeny of 
incrossed cntnap2aΔ25/+cntnap2bΔ7/+ fish at 4 dpf (n=268; cntnap2ab + PTZ, n=6; wild-
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type + PTZ, n=11; cntnap2ab + water, n=11; wild-type + water, n=6; p=0.0013, two-way 
ANOVA, genotype x dose interaction). 
 
Figure 2. cntnap2ab mutants display nighttime hyperactivity.  
A. Experimental setup (Prober et al., 2006; Rihel et al., 2010). 
B. Locomotor activity of cntnap2aΔ25/Δ25cntnap2bΔ7/Δ7 (cntnap2ab, red) and wild-type 
(WT, blue) sibling-matched larvae over 72 h. In total, 838 sibling-matched larvae were 
tracked in 4 independent experiments. Note that hyperactivity in mutants worsens on 
successive nights (arrows). The magnified activity profile on night 6 is shown.  
C. Average locomotor activity of cntnap2ab vs. wild-type on all nights.  (*p=0.00012, 
one-way ANOVA, comparing all genotypes on all nights; p=0.0193, 0.0236, 0.0073, 
nights 4, 5, and 6, respectively.)  
D. Hierarchical clustering of the behavioral fingerprint of cntnap2ab (red arrow) 
compared to the fingerprints of wild-type larvae exposed to a panel of 550 psychoactive 
agents from 4 to 6 dpf (Rihel et al., 2010). Each rectangle in the clustergram represents 
the Z score, or the average value in standard deviations relative to the behavioral 
profiles of wild-type exposed to DMSO alone (magenta, higher than DMSO; cyan, lower 
than DMSO). The cntnap2ab profile correlates with agents that induce nighttime arousal 
(“Correlating Drugs”).  
E. A magnified section of the clustergram, highlighting compounds that correlate with 
the cntnap2ab mutant behavioral fingerprint (red lettering). 
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Figure 3. Differential behavioral responses of cntnap2ab mutants to psychoactive 
agents.  
A. Table of the 14 psychoactive drugs tested in cntnap2aΔ121/Δ121cntnap2b31i/31i and wild-
type larvae, their biological targets, and the rationale for their selection. The following 
classes of drugs are shown: correlating (blue); anti-correlating (purple); drugs 
interacting with the GABA-A receptor (orange); and risperidone (green). 
B, C. Dose-response effects of the NMDA receptor antagonist, (-)-MK-801, on night 
waking activity at 5 dpf (B) and the non-benzodiazepine GABA-A receptor agonist, 
zolpidem, on average night waking activity at 4-6 dpf (C) in wild-type (WT, blue) and 
cntnap2ab (red) larvae (p=0.002, (-)-MK-801; p=0.0003, zolpidem; two-way ANOVA, 
genotype x drug interaction).  
D, E. Rank-sorting shows significant enrichment of NMDA receptor antagonists (D) and 
GABA receptor antagonists (E) in the top ranks of correlating drugs (p=0.031, NMDA-R 
antagonists and p=0.034, GABA-R antagonists; Kolmogorov-Smirnov statistic).  
F. Hierarchical clustering of the behavioral profiles of wild-type or cntnap2ab larvae 
exposed to 14 psychoactive agents across a range of three doses. Each rectangle in 
the clustergram represents the Z-score relative to the behavior of wild-type or mutant 
larvae exposed to DMSO alone (magenta, higher than DMSO; cyan, lower than DMSO).  
G. Magnified sections highlight the behavioral fingerprints of wild-type and cntnap2ab 
larvae in response to zolpidem (20 µM).  
H. Pairwise Euclidean distances between wild-type and cntnap2ab responses to 
psychoactive agents in the principal components analysis (Figures S4A-F). Note that 
zolpidem and (±)-baclofen produce the strongest differential responses. 
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Figure 4. Biochanin A specifically reverses nighttime hyperactivity in cntnap2ab 
mutants.  
A. Rank-sorting of the anti-correlating dataset with respect to estrogenic compounds 
shows significant enrichment of estrogenic agents in the top ranks (p=0.0003 by random 
permutation). Black lines indicate drugs defined as having estrogenic activity (25 
compounds in total). 
B. Hierarchical clustering of the behavioral fingerprints of cntnap2aΔ121/Δ121cntnap2b31i/31i 
larvae exposed to 14 psychoactive agents across a range of three doses relative to the 
wild-type + no drug fingerprint. Each rectangle in the clustergram represents the Z-score 
of compound-exposed mutants relative to untreated wild-type (magenta, higher than 
wild-type; cyan, lower than wild-type).  
C. Magnified sections of the clustergram show relative suppression of the mutant 
fingerprint by biochanin A (0.1 µM) compared to risperidone (0.001 µM). The red box 
highlights the parameters that measure nighttime activity.   
D. Pairwise Euclidean distances (“Differential Drug Effects”) between the mutant 
responses to psychoactive agents compared to untreated wild-type in the PCA (Figure 
S4G). Biochanin A (0.1 µM) produces the strongest suppression of the mutant 
phenotype in this assay, with the fewest side effects on other behavioral parameters. 
Text colors correspond to Figure 3A.  
E, F. Dose-response effects of biochanin A (E) and risperidone (F) on nighttime activity 
at 5 dpf (p=0.0001, biochanin A and p=0.0034, risperidone, two-way ANOVA, gene x 
drug interaction). While there is some experimental variability in the baseline activity of 
both wild-type and mutant larvae, nighttime hyperactivity is consistently observed. 
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G, H. Effect of the blind addition of biochanin A (0.1-1 µM) or DMSO on activity at night 
(G) and day (H) in the progeny of incrosses of cntnap2aΔ25/+cntnap2bΔ7/+ fish at 5 dpf 
(*p=0.045, two-way ANOVA, gene x dose interaction). 
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 CNTNAP2b            GCCTTCACCAGCTCCTCTGTGCTGGCAGCGGATTTTGGTGCCGGCTATGCAAAACTCAAC  
 CNTNAP2b 7         GCCTTCACCAGCTCCT-------GGCAGCGGATTTTGGTGCCGGCTATGCAAAACTCAAC 
                     ****************       ************************************* 
 
 
 
 CNTNAP2b            GCCTCAGA-------------------------------CATTTTCAGGTAACTGGAACT 
 CNTNAP2b 31ins      GCCTCAGAATTTTACCCCAATTTTACCCCAAAGTTACCCCATTTTCAGGTAACTGGAACT  
                     ********                               ********************* 
 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Intron-Exon 4 boundary 
   Exon 2 
 
 
CNTNAP2a            TTACCAGTGGCTGCAGGTCGACCTGGGAAGCAGAAAACAGGTCACAGCCGTCGCCACACA  
CNTNAP2a 121       TTACCAGTGGCTGCAGGTCGACCTG-----------------------------------  
                    *************************                                    
 
CNTNAP2a            GGGTCGATATAGCAGTTCTGATTGGACAACACGATACCGGCTGCTCTATAGTGACACAGG  
CNTNAP2a 121       ------------------------------------------------------------                                                                               
 
          
CNTNAP2a            AAGAAACTGGAAACCATACCATCAAGATGGCAACATCTGGGTGAGTATTAATATAGTGCA 
CNTNAP2a 121       --------------------------ATGGCAACATCTGGGTGAGTATTAATATAGTGCA 
CNTNAP2a 25        AAGAAACTGGAAACC-------------------------GTGAGTATTAATATAGTGCA 
                                                            ******************** 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exon 3-Intron boundary 
!!
 
 
 
CNTNAP2b WT         ACAGCAACATATGGA-------------------------------CATTTTCAGGTAAC  
CNTNAP2b 31ins      ACAGCAACATATGGAATTTTACCCCAATTTTACCCCAAAGTTACCCCATTTTCAGGTAAC  
CNTNAP2b 10        ACAGCAACATATGG-----------------------------------------GTAAC  
CNTNAP2b 148       ACAGCAACATATGG----------------------------------------------  
                    **************                                               
 
CNTNAP2b WT         TGGAACTCAGAGCGAGCCGTGCGACATGAACTTCAGCACCCATTTGTGGCTCGATATGTG  
CNTNAP2b 31ins      TGGAACTCAGAGCGAGCCGTGCGACATGAACTTCAGCACCCATTTGTGGCTCGATATGTG  
CNTNAP2b 10        TGGAACTCAGAGCGAGCCGTGCGACATGAACTTCAGCACCCATTTGTGGCTCGATATGTG  
CNTNAP2b 148       ------------------------------------------------------------ 
                                                                                 
 
CNTNAP2b WT         CGTTTCATCCCACTGGACTGGAGCGAGGAGGGCAGAACTGGCCTGAGGGTGGAAATCTAT  
CNTNAP2b 31ins      CGTTTCATCCCACTGGACTGGAGCGAGGAGGGCAGAACTGGCCTGAGGGTGGAAATCTAT  
CNTNAP2b 10        CGTTTCATCCCACTGGACTGGAGCGAGGAGGGCAGAACTGGCCTGAGGGTGGAAATCTAT  
CNTNAP2b 148       ------------------------------------------------------------ 
 
 
 
CNTNAP2b WT         GGCTGTGCTTACTGGGCAGATGTGATCAGCTTCGATGGCCAGGGAGTGATTTCCTATCGC  
CNTNAP2b 31ins      GGCTGTGCTTACTGGGCAGATGTGATCAGCTTCGATGGCCAGGGAGTGATTTCCTATCGC  
CNTNAP2b 10        GGCTGTGCTTACTGGGCAGATGTGATCAGCTTCGATGGCCAGGGAGTGATTTCCTATCGC  
CNTNAP2b 148       -------------GGGCAGATGTGATCAGCTTCGATGGCCAGGGAGTGATTTCCTATCGC  
                                 *********************************************** !
Exon 3-Exon 4 
Exon 4-Exon 5  
cntnap2b 31 nt-insertion Transcript Sequences 
CNTNAP2a WT        MQPPAGIGLKLLLWILSHISISQAASPSSQKCDEALVTQLLHNAFTSSSVFASSYVPGYA 60 
CNTNAP2a 25       MQPPAGIGLKLLLWILSHISISQAASPSSQKCDEALVTQLLHNAFTSSSVFASSYVPGYA 60 
CNTNAP2a 121      MQPPAGIGLKLLLWILSHISISQAASPSSQKCDEALVTQLLHNAFTSSSVFASSYVPGYA 60 
    ************************************************************ 
 
CNTNAP2a WT        KLNKRGGAGGWSPLDSDHYQWLQVDLGSRKQVTAVASQGRYSSSDWTTRYRLLYSDTGRN 120 
CNTNAP2a 25       KLNKRGGAGGWSPLDSDHYQWLQVDLGSRKQVTAVASQGRYSSSDWTTRYRLLYSDTGRN 120 
CNTNAP2a 121      KLNKRGGAGGWSPLDSDHYQWLQVDL--------MATSG--------------------- 91 
    **************************        :*:.*                      
 
CNTNAP2a WT        WKPYHQDGNIWAFAGNSNTESVVRHDLQNPVVARYLRIIPLDWSEEGRIGLRFEIYGCPY 180 
CNTNAP2a 25       WKPHLQGTPIQRVWFG----MTCKTRLWPVICASFL*        152 
CNTNAP2a 121      ---HLQGTPIQRVWFG----MTCKTRLWPVICASFL*        120 
       : *.  *  .  .     . :  *   : * :*  !!!!!!!
!
CNTNAP2b WT         MRRIVGLEVPLILWIWCVYVKLSTGAQRCDEVLASPLPYSAYTSSSVLAADFGAGYAKLN  60 
CNTNAP2b  7         MRRIVGLEVPLILWIWCVYVKLSTGAQRCDEVLASPLPYSAYTSSWQRILVPAMQNSTGE* 60 
CNTNAP2b 31ins      MRRIVGLEVPLILWIWCVYVKLSTGAQRCDEVLASPLPYSAYTSSSVLAADFGAGYAKLN  60
CNTNAP2b  10        MRRIVGLEVPLILWIWCVYVKLSTGAQRCDEVLASPLPYSAYTSSSVLAADFGAGYAKLN  60 
CNTNAP2b  148       MRRIVGLEVPLILWIWCVYVKLSTGAQRCDEVLASPLPYSAYTSSSVLAADFGAGYAKLN  60 
                    *********************************************       .   :. : 
 
 
CNTNAP2b WT         RRVGNGGWSPSDSDRYRWLQVDLRARKQITAIATQGRYSSSDWTKNYRLLYSDTGSNWKP  120 
CNTNAP2b 31ins      RRVGNGGWSPSDSDRYRWLQVDLRARKQITAIATQGRYSSSDWTKNYRLLYSDTGSNWKP  120 
CNTNAP2b  10        RRVGNGGWSPSDSDRYRWLQVDLRARKQITAIATQGRYSSSDWTKNYRLLYSDTGSNWKP  120 
CNTNAP2b  148       RRVGNGGWSPSDSDRYRWLQVDLRARKQITAIATQGRYSSSDWTKNYRLLYSDTGSNWKP  120 
                      ...   : :.:. *** .   .  :     *  .  :... * .     . *******      
 
 
CNTNAP2b WT         YRQDSNIWTFSGNWNSE--------RAVRHELQHPFVARYVRFIPLDWSEEGRTGLR-VE  171 
CNTNAP2b 31ins      YRQDSNIWNFTPILPQSYPIFR*            142 
CNTNAP2b  10        YRQDSNIWVTG-------------TQSEPCDMNFSTHLWLDMCVSSHWTGARRAELA*    164 
CNTNAP2b 148       YRQDSNIWGQM*             131 
       ******** !!!!!!!!!!!!!!!!!!!!!
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Table S1. Head and Brain Size Measurements in Wild-type (WT) and 
cntnap2aΔ121/Δ121cntnap2b31i/31i Mutants at 30 and 96 hpf. 
 
 
 
 
 
At 30 hpf: WT N=22; Mutant N=24; 96 hpf: WT N=9; Mutant N=7; 96 hpf brains WT N=11, Mutant N=14. 
For yolk size measurements at 30 hpf: WT N=21; Mutant N=23. 
 
 
 
 
 
 
 
 
Age 
Head Size  
(Rel. to WT) 
(± SEM) 
 
 
p 
Eye Size  
(Rel. to WT) 
(± SEM) 
 
 
p 
Yolk Size  
(Rel. to WT) 
(± SEM) 
 
 
p 
 
30 hpf 
 
0.935 ± 0.00783 
 
9.71x10-7 
 
0.851 ± 0.0190 
 
1.50x10-6 
 
0.902 ± 0.00613 
 
0.00132 
 
96 hpf 
 
0.903  ± 0.0236 
 
0.00513 
 
0.873 ± 0.0198 
 
0.00106 
 
N/A 
 
N/A 
 
96 hpf 
brain 
 
0.820  ± 0.0226 
 
3.89x10-6 
 
N/A 
 
N/A 
 
N/A 
 
N/A 
Age                 Head:Eye Ratio                 Head:Yolk Ratio 
 WT Mutant p WT Mutant p 
 
30 hpf 
 
4.80 ± 0.0679 
 
5.33 ± 0.112 
 
0.00082 
 
0.574 ± 0.00672 
 
0.595 ± 0.0068 
 
0.11 
 
96 hpf 
 
2.14 ± 0.0549 
 
2.21 ± 0.0795 
 
0.458 
 
N/A 
 
N/A 
 
N/A 
Table S2. Rest-Wake Cycle Parameters in Background-Matched Wild-type and 
cntnap2aΔ25/Δ25cntnap2bΔ7/Δ7 Larvae at 4-6 dpf. 
 
 
 
 
 
 
Time Wild-type cntnap2ab p Wild-type cntnap2ab p Wild-type cntnap2ab p 
 Total Sleep (minutes) Number of Sleep Bouts Sleep Bout Length (minutes) 
Night 4 453 ± 11.1 414 ± 16.7 0.0451 59.8 ± 3.57 64.0 ± 3.76 0.4143 11.0 ± 1.07 8.47 ± 0.853 0.0793 
Night 5 362 ± 16.0 324 ± 21.0  0.1459 76.9 ± 3.44 75.4 ± 4.08 0.7826 6.28 ± 0.709 5.94 ± 0.945 0.7714 
Night 6 342 ± 15.9 309 ± 19.6 0.194 81.1 ± 3.45 81.8 ± 4.29 0.8973 6.09 ± 0.939 5.53 ± 1.04 0.6904 
Day 5 351 ± 29.3 417 ± 34.8 0.1448 66.3 ± 5.44 59.5 ± 4.09 0.3132 6.85 ± 0.759 7.12 ± 0.779 0.8068 
Day 6 
 
234 ± 26.8 283 ± 32.2 0.2459 59.9 ± 4.70 73.0 ± 7.15 0.1159 4.01 ± 0.697 4.51 ± 0.714 0.6186 
 Sleep Latency (minutes) Average Activity (seconds/minute) Waking Activity (seconds/minute) 
Night 4 17.0 ± 0.493 21.1 ± 3.73 0.2264 0.281 ± 0.0315 0.440 ± 0.0783 0.0478 0.916 ± 0.0588 1.00 ± 0.0880 0.4103 
Night 5 12.0 ± 1.61 10.3 ± 0.902 0.372 0.363 ± 0.0342 0.596 ± 0.103 0.0234 0.767 ± 0.059 0.969 ± 0.104 0.0825 
Night 6 7.46 ± 0.820 9.81 ± 1.22 0.1025 0.349 ± 0.0257 0.649 ± 0.139 0.0222 0.659 ± 0.0310 0.940 ± 0.144 0.0394 
Day 5 3.60 ± 1.14 4.69 ± 1.58 0.5695 1.88 ± 0.177 1.57 ± 0.212 0.2615 2.89 ± 0.189 2.47 ± 0.212 0.137 
Day 6 13.2 ± 7.86 7.07 ± 2.13 0.4878 2.42 ± 0.190 2.037 ± 0.215 0.1817 3.19 ± 0.209 2.72 ± 0.253 0.1462 
Table S3. Acoustic Startle, Habituation, and Optokinetic Response Assays in 
Wild-type and cntnap2aΔ121/Δ121cntnap2b31i/31i Larvae at 5-7 dpf. 
              
 
 
Acoustic Startle and Habituation 
 
 
 
 
 
 
    
aTested in background-matched controls.bp = 0.025, cp =0.039, t-test 
 
 
Optokinetic Response 
 
dp = 0.04, ep =0.036, t-test 
 
 Short Latency C-bend (SLC)a 
Sensitivity (% Response) 
Long Latency C-bend (LLC)a 
(% Response) 
SLC 
Habituation 
Prepulse 
Inhibition 
Genotype 13 dB  26 dB  13 dB  19.8 dB Average (%) Average (%) 
Wild-type 7.5 ± 2.45 83.7 ± 4.27 22.9 ± 3.36 37.2 ± 4.1b 96.2 ± 1.07 64.0 ± 3.35 
cntnap2aΔ121/+2b31i/+ 10.6 ± 1.22 86.9 ± 1.87 23.6 ± 2.16 34.1 ± 2.23c 95.5 ± 1.12 60.0 ± 3.09 
cntnap2aΔ121/Δ121 2b31i/31i 8.89 ± 2.41 89.4 ± 3.92 15.6 ± 5.00 22.6 ± 4.62b,c 97.4 ± 0.97 62.3 ± 3.66 
Genotype % contrast (# saccades/min ± SEM) Spontaneous 
Saccades 100 70 40 20 10 5 
Wild-type 10.3 ± 0.52d 10.3 ± 0.67 8.04 ±0.51 6.99 ± 0.45 6.34 ± 0.52 5.9 ± 0.52 5.59 ± 0.45 
cntnap2aΔ121/+2b31i/+ 10.4 ± 0.49e 9.59 ± 0.61 8.07 ± 0.46 6.84 ± 0.55 5.87 ± 0.43 5.69 ± 0.36 4.95 ± 0.50 
cntnap2aΔ121/Δ121 2b31i/31i 8.74 ± 0.47d, e 8.72 ± 0.43 6.49 ± 0.53 5.60 ± 0.53 5.15 ± 0.49 4.84 ± 0.44 5.67 ± 0.42 
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Supplemental Data 
 
Figure S1. Generation of cntnap2ab mutants and characterization of brain 
structure. 
A, B. Fluorescent in situ hybridization of cntnap2a and cntnap2b expression and 
acetylated tubulin in wild-type embryos at 30 and 48 hpf.  
C. Whole mount in situ hybridization of cntnap2a and cntnap2b in wild-type embryos at 
24 and 48 hpf. Both paralogs are expressed in the CNS, though cntnap2b shows a 
more specific expression pattern in the telencephalon and diencephalon (24 hpf), the 
optic tectum, midbrain-hindbrain boundary, and hindbrain (48 hpf).  
D. Genomic sequences of insertion-deletion mutations generated by zinc finger 
nucleases in each cntnap2 paralog. These include Δ121 and Δ25 in exon 3 of cntnap2a 
(top) and Δ7 in exon 2 and a 31-nt insertion in exon 4 of cntnap2b (bottom), all of which 
produce a frameshift and premature stop codon.  
E. Alternatively spliced transcripts resulting from the 31-nt allele in exon 4 of cntnap2b 
identified by RT-PCR of exons 1 to 6 at 5 dpf. These transcripts include: (i) the 31-nt 
sequence itself, as in the genomic sequence; (ii) Δ10 in exon 4: because the 31-nt 
insertion occurs close to the intron-exon 4 boundary, an alternate splice site is used (the 
next “TCAG” in the genomic sequence after the actual intronic splice site), which is 10 nt 
after the beginning of exon 4; (iii) Δ148 due to splicing of the entire exon 4. All 3 
transcripts produce a frameshift and a premature stop codon. We did not identify 
alternatively spliced transcripts resulting from the other mutations in either gene.  
F. Sequence alignment of wild type Cntnap2a (top) and Cntnap2b (bottom) proteins and 
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the translation of mutant transcripts. All mutant transcripts are predicted to cause 
premature stop codons in the discoidin domains of both proteins (Figure 1A).  
G-I. Acetylated tubulin (AcTub) and synaptic vesicle protein 2 (SV2) labeling in wild-type 
(G-I) and cntnap2aΔ121/Δ121cntnap2b31i/31i (G’-I’) fish at 24, 48, and 120 hpf. While there 
is a transient delay in the formation of the anterior and post-optic commissures in 
cntnap2ab mutants at 28 hpf (see K, K’, M), these commissures form by later stages. 
Brain structure is not otherwise grossly disrupted in cntnap2ab mutants up to 120 hpf. 
J-K. Acetylated tubulin and GABA (J, J’) or GFAP (glial cells) (K, K’) in wild-type and 
cntnap2aΔ121/Δ121cntnap2b31i/31i (cntnap2ab) mutants at 28 hpf.  
L. There are significantly fewer GABA+ cells in both the telencephalon (arrowheads) 
and diencephalon (double arrowheads) of cntnap2ab (J’) versus wild-type (J) larvae at 
28 hpf. GABA+ cells were counted in z-stack images by three blinded raters. 
(*p=0.00782, telencephalon; **p=0.0181, diencephalon, two-way ANOVA, genotype 
factor.)  
M. The formation of the anterior commissure (AC) and post-optic commissure (POC) is 
delayed in cntnap2aΔ121/Δ121cntnap2b31i/31i (cntnap2ab) (K’) compared to wild-type (K) 
larvae (*p=0.00428, AC; **p=0.0159, POC, two-way ANOVA, genotype factor.) Three 
blinded raters quantified the degree of commissure formation based on a qualitative 
rating scale ranging from no axons crossing (1) to complete formation (7), as previously 
described (Barresi et al., 2005). The POC appears to be less fasciculated in mutants. 
Glial bridge formation is largely intact.  
N-R Head and brain size in wild-type (N-Q) and cntnap2aΔ121/Δ121cntnap2b31i/31i 
(cntnap2ab) (N’-Q’). Representative tracings done in Fiji are shown in yellow. The 
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posterior boundaries of the head and brain were defined by the otic vesicle and the 
midbrain-hindbrain boundary, respectively.  
R. cntnap2ab mutant heads are 6.5% and 9.7% smaller than wild-type at 30 hpf and 96 
hpf, respectively, and mutant brains are 18% smaller than wild-type at 96 hpf. 
(*p=9.71x10-7, 30 hpf head size; **p=0.00513, 96 hpf head size; ***p=3.89x10-6, 96 hpf 
brain size; one-way ANOVA). In addition, eye and yolk size measurements indicate that 
mutant fish are smaller overall (Table S1).  
(A, B): frontal views; (C, N-O, N’-O’): lateral views; (G-J, G’-J’, P-P’): lateral views of 
dissected embryos with the eye removed; (K-K’): frontal views of the forebrain; (Q-Q’): 
ventral views; tel, telencephalon; di, diencephalon; OT, optic tectum; PC, posterior 
commissure; AC, anterior commissure; POC, post-optic commissure; E, eye; MHB, 
midbrain-hindbrain boundary; HB, hindbrain. 
 
Figure S2. Inhibitory and excitatory neurons in cntnap2ab mutants.  
Immunostainings of reporter gene expression in Tg(dlx6a-1.4kbdlx5a/dlx6a:GFP) and 
Tg(vglut:DsRed) in wild-type (A-H) and cntnap2aΔ121/Δ121cntnap2b31i/31i (A’-H’) larvae at 
4 dpf. (A-A’, E-E’): The deficit in GABAergic neurons and precursors (dlx5a6a:GFP+ 
cells) is evident in the ventral and dorsal telencephalon (tel), hypothalamus (hyp), and 
cerebellum (CB) (arrowheads in A-A’, E-E’). The reduction in GABAergic neurons by 
surface area of acetylated tubulin is significant in the forebrain and cerebellum (J). 
I-K. dlx5a6a:GFP+, vglut:DsRed and acetylated tubulin were quantified by brain region 
at 4 dpf: forebrain (small brackets in D-D’, H-H’); hypothalamus (large brackets in D-D’, 
H-H’); cerebellum (arrowheads in E-E’, H-H’); and optic tectum (arrowheads in E-E’, H-
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H’). (forebrain and hypothalamus: wild-type, n=9; cntnap2ab, n=9; optic tectum and 
cerebellum: wild-type, n=7; cntnap2ab, n=8) 
I. dlx5a6a:GFP+ cell number normalized to wild-type. (*p<0.001; **p<0.01; ***p<0.02; 
one-way ANOVA, Bonferroni corrected). 
J. dlx5a6a:GFP+ cell number relative to acetylated tubulin surface area normalized to 
wild-type. Because there are significant reductions in GABAergic neurons relative to 
area in the forebrain and cerebellum, we concluded that the GABAergic deficits in these 
regions are not primarily attributable to the reduction in brain size. (*p<0.02; one-way 
ANOVA, Bonferroni corrected). 
K. vglut:DsRed surface area relative to acetylated tubulin surface area normalized to 
wild-type. Unlike GABAergic neurons, there are no significant reductions in 
glutamatergic surface area relative to acetylated tubulin surface area across regions, 
suggesting these differences are due to the overall reduction in brain size as opposed to 
regional deficits (p=0.225, forebrain; p=0.444, hypothalamus; p=0.408, optic tectum; 
p=0.490, cerebellum; one-way ANOVA). 
L-S. Analysis of the CNS of wild-type (L-S) and cntnap2aΔ121/Δ121cntnap2b31i/31i 
(cntnap2ab) (L’-S’) by in situ hybridization at 48 hpf: (L, L’): glutamate decarboxylase 
1b (gad1b); (M, M’): vesicular glutamate transporter or solute carrier family 17, member 
6b (vglut2a or slc17a6b); (N, N’): solute carrier family 6 (neurotransmitter transporter, 
glycine), member 5 (glyt2 or slc6a5); (O, O’): tyrosine hydroxylase (th1 or th); (P, P’): 
neuronal differentiation 1 (neurod or neurod1); (Q, Q’); transiently expressed axonal 
glycoprotein (tag1) or contactin 2 (cntn2); (R, R’): TUNEL staining at 28 hpf; (S, S’): 
phospho-histone H3 (H3P) (green) and acetylated tubulin (blue) immunostaining at 48 
 5 
hpf. We observed that expression of gad1b was variable. No gross differences in the 
other neurotransmitter systems, markers of neuronal differentiation, apoptosis, or cell 
proliferation were observed.  
(A-D, A’-D’, E-H, E’-H’) show all channels for the images in Figure 1C-1F and 1C’-F’, 
respectively. (A-D, A’-D’): ventral views; (E-H, E’-H’, L-N, L’-N’; P-P’, R-R’, S-S’): lateral 
views; (O-O’, Q-Q’): dorsal views. (tel,  telencephalon; hyp, hypothalamus; OT, optic 
tectum; CB: cerebellum; HB, hindbrain; E, eye.) 
 
Figure S3. Drug-induced seizure sensitivity and nighttime hyperactivity in 
cntnap2ab mutants. 
A. Activity tracings of wild-type (WT) and cntnap2aΔ121/Δ121cntnap2b31i/31i (cntnap2ab) 
larvae at 6 dpf before and after exposure to 10 mM PTZ or water (ribbon shows +/- 
SEM).  
B. Average activity 1 h before and after the blind addition of 10 mM PTZ or water to the 
progeny of incrosses of cntnap2aΔ25/+cntnap2bΔ7/+ fish, as in Figure 1H, with 
intermediate genotypes shown. Note that cntnap2aΔ25/Δ25cntnap2bΔ7/Δ7 larvae show the 
greatest PTZ response (p=0.0013, two-way ANOVA, genotype x dose interaction).  
C. Dose-response curve showing the percent increase in activity over baseline per fish 
of wild-type or cntnap2aΔ121/Δ121cntnap2b31i/31i larvae at 6 dpf exposed to water or 
increasing concentrations of PTZ for 1 h (p=0.0004, two-way ANOVA, genotype x dose 
interaction). Inset shows that the average baseline activity for 1 h prior to the addition of 
water or PTZ is not significantly different in wild-type and cntnap2ab larvae.  
D. Dose-response curve of the log of the percent increase in activity over baseline per 
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fish for wild-type and cntnap2aΔ121/Δ121cntnap2b31i/31i larvae at 4 dpf exposed to water or 
increasing concentrations of PTZ for 1 h. Compared to larvae at 6 dpf (C), baseline 
activity at 4 dpf is relatively low, such that the PTZ response (normalized to baseline) 
appears greater. Increased PTZ sensitivity in mutants is evident at 4 dpf as well (p<10-6, 
two-way ANOVA, genotype x dose interaction). cntnap2ab mutants decrease their 
activity in response to water, in contrast to wild-type fish, in which water is mildly 
activating. We hypothesize this difference may reflect deficits in the ability of cntnap2ab 
mutants to respond to mildly stressful stimuli. Given this observation, normalization in 
the dose-response experiments was done to baseline, pre-PTZ activity per fish.  
E. Cumulative histogram showing the percent of all activity in the blinded experiment 
that occurred 1 h after the addition of PTZ or water (ribbon shows +/- SEM). Most 
(>90%) baseline activity of 4 dpf larvae is ≤0.3/sec, though PTZ induces robust 
increases in activity. cntnap2ab mutants are more likely than background-matched wild-
type larvae to have activity bouts 0.5/sec in response to PTZ. Inset shows the average 
activity (± SEM) centered on all locomotor events that occurred within 1 h of the addition 
of PTZ or water. Note that PTZ-induced activity bouts occur more sparsely in mutants 
compared to wild-type, as evidenced by the decreased likelihood of a bout to be 
immediately preceded or followed by another bout (arrowheads).  
F. Plot of average activity by cntnap2 allele before and after the blind addition of 10 mM 
PTZ or water at 6 dpf. This graph highlights that increased sensitivity to PTZ is primarily 
driven by the cntnap2b allele (p=0.5703, a allele x drug interaction; p=0.0046, b allele x 
drug interaction; p=0.10, a allele versus b allele interaction, two-way ANOVA).  
G. Rest-wake locomotor activity of cntnap2aΔ25/Δ25cntnap2bΔ7/Δ7 (cntnap2ab, red) and 
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wild-type (blue) sibling-matched larvae over 72 h, as in Figure 2B. The bar graph shows 
the average locomotor activity of wild-type, cntnap2aΔ25/Δ25cntnap2bΔ7/Δ7 and all 
intermediate genotypes on all nights. We observed a general trend in strengthening of 
the phenotype with a reduction in cntnap2ab gene dosage (see also Figure S3H). 
(*p=1.2x10-4, one-way ANOVA followed by Tukey’s post-hoc testing shows the 
differences lie between the double homozygous larvae and the genotypes marked with 
the black bar.)  
H. Locomotor activity of cntnap2aΔ121/Δ121cntnap2b31i/31i (cntnap2ab, red) and wild-type 
(blue) background-matched larvae over 72 h. In total, 187 larvae were tracked blind to 
genotype. Magnified graphs of activity on each night are shown. The bar graph shows 
average locomotor activity of wild-type, cntnap2aΔ121/Δ121cntnap2b31i/31i and all 
intermediate genotypes on all nights. Note that double homozygous mutants 
demonstrate the greatest level of activity, though single homozygotes for the cntnap2b 
mutation (cntnap2a+/+cntnap2b31i/31i or cntnap2a+/-cntnap2b31i/31i larvae) are hyperactive 
as well, indicating the cntnap2b allele may be driving the hyperactivity phenotype in this 
line (*p=0.0198, all nights, one-way ANOVA followed by Tukey’s post-hoc testing shows 
the differences lie between the double homozygous larvae and the genotypes marked 
with the black bar.) The difference in the relative allelic effects in the two mutant lines 
may be due to background variation that influences allelic expression, the smaller 
dataset for the cntnap2aΔ121/Δ121cntnap2b31i/31i line, or the nature of the mutations 
themselves, i.e. alternatively spliced transcripts. However, the effect of total disruption 
of Cntnap2 on nighttime activity in double homozygotes is robust and consistent in both 
mutant lines. 
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Figure S4. Differential pharmacological responses of cntnap2ab mutants and 
suppression of nighttime hyperactivity by estrogens. 
A. Magnified sections of the clustergram of the behavioral profiles of wild-type (WT) or 
cntnap2aΔ121/Δ121cntnap2b31i/31i (MUT) larvae exposed to 14 psychoactive agents (as in 
Figure 3F) show differential responses to zolpidem (10 µM, 20 µM). Each rectangle in 
the clustergram represents the Z-score relative to the behavior of wild-type or 
cntnap2aΔ121/Δ121cntnap2b31i/31i larvae exposed to DMSO alone (magenta, higher than 
DMSO; cyan, lower than DMSO). The eigenvectors for the first four PCA components 
are plotted below the clustergram to show the relative contribution of the 18 rest-wake 
cycle parameters (above) to each PCA component. Compared to the 26 rest-wake 
parameters, as shown in Figure 2E, in subsequent hierarchical clustering and PCA 
analyses (Figures 3F and 4B), the length and latency parameters were removed, 
because these parameters are non-normally distributed across drug-exposed samples, 
thereby skewing the PCA analysis.  
B. Scree plot showing the percentage of the variance that is explained by each principal 
component in the PCA. Note that four components explain ~50% of the variance. The 
first four components are shown in magenta, green, blue, and yellow, respectively, 
corresponding to the components plotted in (A).  
C-E. To confirm the stability of the PCA, we asked how the distribution of eigenvectors 
would change if each drug-dose combination was removed sequentially from the 
dataset, following the method of (Woods et al., 2014). We applied this “left-out” 
modeling approach to our dataset (black) and to a randomized permutation of our 
dataset (orange).  
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C. Plot of the cumulative probability versus the similarity of eigenvectors for the “left-out” 
models of our dataset (black) and the randomized dataset (orange). The eigenvectors 
remain more similar in our model compared to the randomized dataset.  
D. Plot of cumulative probability versus length in the “left-out” models shows that the 
distance from the origin of eigenvectors in our dataset (black) is greater compared to 
the randomized dataset (orange).  
E. Comparison of the distances between vectors for each drug-dose combination in the 
“left-out” model of our dataset (black dots) versus the randomized set (orange dots). 
Observe that in our model, the spatial distance between eigenvectors is relatively 
maintained, unlike in the randomized dataset.  
F. Wild-type (blue) and cntnap2aΔ121/Δ121cntnap2b31i/31i (cntnap2ab, red) behavioral 
responses to the three doses of zolpidem (solid lines) and (±)-baclofen (dashed lines) 
can be represented by plotting the first two components of the PCA. Note the distinct 
location and shape of the wild-type and mutant plots, indicating that these drugs induce 
differential responses, as shown quantitatively for zolpidem in Figure 3C. In contrast, 
plots of the first two components of the PCA showing the behavioral responses to three 
doses of clonidine (F) (gray) in wild-type (thick line, blue dots) and cntnap2ab (thin line, 
red dots) are shown. Note that the location and shape of the mutant and wild-type 
curves is similar for clonidine, which indicates that this drug has a similar behavioral 
effect in wild-type and mutant larvae, unlike zolpidem and baclofen. The unlabeled dots 
represent the responses of wild-type (blue) and cntnap2ab (red) larvae to other drugs in 
PCA space. A representative plot of average night activity at 4 dpf for clonidine (inset) 
shows that clonidine induces similar dose-dependent behavioral effects on nighttime 
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activity at 4 dpf in wild-type (blue) and cntnap2ab (red) larvae (p=0.744, two-way 
ANOVA, genotype x drug interaction).  
G. Magnified section of the clustergram in Figure 4B. Observe that biochanin A (0.1 μM, 
1 μM) and three doses of β-estradiol 17-cypionate (0.1, 1, and 10 μM) are in this 
cluster, which highlights the drugs that induce the strongest phenotypic suppression. 
Each rectangle in the clustergram represents the Z-score of mutants relative to wild-
type + no drug (cream color = wild-type level; magenta, higher than wild-type; cyan, 
lower than wild-type). The eigenvectors for the first three PCA components are plotted 
below the clustergram to show the relative contribution of the rest-wake cycle 
parameters (above) to each PCA component, as in (A). The red box highlights the 
parameters that measure nighttime activity. Scree plot (lower left inset) shows that three 
components explain ~50% of the variance. These components are shown in magenta, 
green, and blue, respectively, corresponding to the components plotted on the graph. 
The stability of the PCA was confirmed using the “left-out” model (Woods et al., 2014), 
as in (B-E) (data not shown). Of note, we found that the lowest dose of risperidone 
(0.001 μM) reverses nighttime hyperactivity in cntnap2ab mutants, yet based on the 
PCA, it appears to rescue with less phenotypic selectivity than biochanin A (Figure 4C, 
D, F), suggesting that its effect on nighttime hyperactivity is less phenotypically specific. 
At the same time, the effects of risperidone appear to be highly dose-dependent, 
suggesting that it may affect various pharmacological pathways at different dose 
ranges. Further experiments are needed to investigate the differential responses of wild-
type and mutant larvae to risperidone across a range of doses.  
H. The top anti-correlating psychoactive agents and their degree of anti-correlation 
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relative to the cntnap2aΔ25/Δ25cntnap2bΔ7/Δ7 mutant behavioral profile. Drugs shown in 
bold purple letters were selected for further testing in wild-type and mutant fish (Figure 
3A). It is possible that other agents on this list in addition to biochanin A may have the 
ability to suppress the mutant behavioral phenotype. It will be interesting in future 
studies not only to test all of the anti-correlating small molecules, but to test all 550 
psychoactive agents in cntnap2ab and other zebrafish mutants of ASD genes, which will 
provide substantial leverage to investigate convergent biological mechanisms among 
ASD risk genes. 
I. Locomotor activity of cntnap2aΔ121/Δ121cntnap2b31i/31i (red) and wild-type (blue) non-
background-matched larvae over 72 hours (n=40 per group). cntnap2ab mutants display 
nighttime hyperactivity relative to unrelated wild-type (*night 5, p=0.0079; **night 6, 
p=0.022; one-way ANOVA), consistent with our findings in background-matched larvae. 
Mutants also show significantly less daytime activity relative to unrelated wild-type 
controls (p=0.005, one-way ANOVA). Because this effect did not reach statistical 
significance in sibling-matched control experiments (Table S2), we concluded that this 
difference is likely due to background or environmental variation. 
J. Effect of β-estradiol (1 μM) on average night waking activity at 5 dpf in wild-type and 
cntnap2aΔ121/Δ121cntnap2b31i/31i larvae (*p=0.017, two-way ANOVA, genotype x drug 
interaction). 
K. To assess the extent to which biochanin A reverses PTZ-induced seizures, wild-type 
and cntnap2aΔ121/Δ121cntnap2b31i/31i mutants were exposed daily and chronically to 
biochanin A (1 μM) or DMSO from 24 hpf to 4 dpf, and then exposed to PTZ in the 
presence of biochanin A or DMSO. Exposure to biochanin A did not rescue the 
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increased sensitivity of cntnap2ab mutants to PTZ (p=0.237, three-way ANOVA, 
genotype x drug exposure x PTZ interaction). cntnap2ab mutants demonstrated 
increased sensitivity to PTZ irrespective of biochanin A exposure (p=3.57x10-4, 
genotype x PTZ exposure).  
L. To assess the extent to which long-term exposure to biochanin A reverses nighttime 
hyperactivity, wild-type and cntnap2aΔ121/Δ121cntnap2b31i/31i (cntnap2ab) embryos were 
exposed daily to biochanin A (1 μM) or DMSO alone beginning at 24 hpf. After removal 
of the drug solution at 4 dpf, the locomotor activity of wild-type and cntnap2ab larvae 
was quantified for 48 hours using the automated tracking assay. Exposure to biochanin 
A followed by washout did not rescue nighttime hyperactivity (*p=5.51x10-5, two-way 
ANOVA, genotype factor; p=0.454, two-way ANOVA, genotype x drug interaction).  
M. To determine whether early exposure to biochanin A reverses the GABAergic deficits 
in cntnap2ab mutants, wild-type and cntnap2aΔ121/Δ121cntnap2b31i/31i (cntnap2ab) 
embryos were exposed to biochanin A (0.1 μM) beginning at 30 hpf. Immunostainings of 
reporter gene expression using the transgenic line, Tg(dlx6a-1.4kbdlx5a/dlx6a:GFP), 
were performed and dlx5a/6a:GFP+ cells in the forebrain of wild-type and cntnap2ab 
mutants at 4 dpf were counted manually. There are significantly fewer GABAergic 
neurons in the forebrains of cntnap2ab mutants compared to wild-type larvae at 4 dpf 
irrespective of exposure status (*p=6.03x10-13, two-way ANOVA, genotype factor). Early 
exposure to biochanin A did not alter the number of GABAergic neurons in cntnap2ab or 
wild-type fish (p=0.190, two-way ANOVA, genotype x drug interaction; wild-type + 
DMSO, n=13; wild-type + biochanin A, n=17; cntnap2ab + DMSO, n=14; cntnap2ab + 
biochanin A, n=15). 
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N. To ascertain the extent to which biochanin A (BchA) upregulates estrogen response 
genes, expression of three known estrogen target genes (cytochrome P450, family 19, 
subfamily A, polypeptide 1 (aromatase B, cyp19a1b); vitellogenin 1 (vtg1); estrogen 
receptor 1 (esr1)) (Hao et al., 2013) was measured by qPCR in total RNA extracts from 
wild-type larvae exposed overnight to biochanin A (1 μM, 10 μM) or DMSO from 4 to 5 
dpf. Fold change in gene expression is shown. Note that biochanin A (10 μM) 
significantly activates estrogen response genes, while the rescue dose (1 μM) has only 
a weak effect (*p=0.001; **p=0.002; #p=0.1; Dunnett’s test). 
 
Table S1. Head and Brain Size Measurements in Wild-type and 
cntnap2aΔ121/Δ121cntnap2b31i/31i Mutants at 30 and 96 hpf. 
 
Table S2. Rest-wake Cycle Parameters in Background-Matched Wild-type and 
cntnap2aΔ25/Δ25cntnap2bΔ7/Δ7 Larvae at 4-6 dpf. 
 
Table S3. Acoustic Startle, Habituation, and Optokinetic Response Assays in 
Wild-type and cntnap2aΔ121/Δ121cntnap2b31i/31i Larvae at 5-7 dpf.  
Note on Table S3: While there were no significant differences in acoustic startle, 
habituation, or pre-pulse inhibition (PPI) in cntnap2aΔ121/Δ121cntnap2b31i/31i fish at 5 to 7 
dpf, mutants were significantly less likely to perform long-latency “C-bends” (LLC) in 
response to a 19.8 dB acoustic stimulus. LLC responses are kinematically distinct from 
short-latency C-bend startle responses (SLC) and have different genetic and neural 
circuit requirements than SLC responses. While the specific neurons required for LLC 
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behavior are not well understood, LLC-like responses may be involved in coordinated 
escape movements in schooling fish (Burgess and Granato, 2007). In addition, we did 
not detect differences in spontaneous saccadic eye movements or OKR performance at 
most contrast sensitivities in cntnap2ab mutants at 5 to 7 dpf, though at the highest 
contrast level (100%), mutants displayed significantly lower OKR performance 
compared to wild-type fish. The absence of robust phenotypes in these larval behavioral 
assays further supports the specificity of the nighttime hyperactivity phenotype detected 
in our rest-wake assay. Further studies are indicated to dissect the deficits in circuitry 
underlying these subtle behavioral differences. 
 
Supplemental Experimental Procedures 
 
Zinc finger nuclease design 
CompoZr custom zinc finger nucleases (ZFN) targeting zebrafish cntnap2a and 
cntnap2b were designed by Sigma-Aldrich. CompoZr ZFN contain a DNA-binding 
domain and an obligate-heterodimer FokI nuclease domain, engineered for improved 
specificity (Miller et al., 2007). Activity of ZFN pairs as determined by the yeast MEL-1 
reporter assay (Doyon et al., 2008) was >50% for all pairs (cntnap2a, 115.1%; 
cntnap2b, Exon 2, 141.0%; cntnap2b, Exon 4: 86.3%). Target sequences for each ZFN 
pair are shown below. ZFN left and right array binding sites are in capital letters and the 
cut sites are shown in bold lower case letters. 
cntnap2a, Exon 3: AACTGGAAACCATaccatcAAGATGGCAACATCTGGG 
cntnap2b, Exon 2: AGCGCCTTCACCAGCTCCtctgtgCTGGCAGCGGAT 
cntnap2b, Exon 4: CTCTTCTTTCTGCCTCAGAcattttCAGGTAACTGGAACTCAG 
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Generation and screening of cntnap2ab double mutants 
To generate mutants, 25, 50, or 75 pg of each left and right ZFN mRNA directed 
against either cntnap2a or cntnap2b was injected into wild-type embryos (F0) at the one-
cell stage. Plasmids encoding ZFN (pZFN) were linearized by XhoI digestion. Capped 
mRNA was synthesized by in vitro transcription and the polyA tail was added using the 
mMessage mMachine T7 Ultra transcription kit (Ambion) following the manufacturer’s 
protocol. mRNA was purified using the RNeasy Mini Kit (Qiagen). Each ZFN set was 
screened to determine the optimal concentration that induced somatic mutations at the 
target site while minimizing toxicity, as previously described (Foley et al., 2009; Sander 
et al., 2011). In brief, genomic DNA was isolated from 10 injected 24 hpf embryos that 
were viable and lacked developmental defects, and the ZFN target region was amplified 
by limited-cycle PCR and cloned using the TOPO-TA kit (Invitrogen). The somatic 
mutation frequency was determined based on the number of insertion-deletion 
mutations observed by high-resolution fragment analysis of PCR-amplified plasmid DNA 
from 100 transformed colonies. The following somatic mutation frequencies were 
ascertained for each ZFN set: cntnap2a: 36%, cntnap2b, Exon 2: 70%, cntnap2b, Exon 
4: 12%. Morphologically normal embryos were raised to adulthood and screened for 
germline mutations, according to the method described in (Cifuentes et al., 2010), with 
some modifications. Briefly, to genotype the progeny of intercrossed founders, 32 F1 
embryos were screened in groups of two, which were sorted into the wells of a 96-well 
plate. 50 μl of 100 mM NaOH was added to each well and the embryos were boiled for 
20 minutes at 95°C, producing a crude DNA extract, which was neutralized by the 
addition of 15 μl of 1 M Tris-HCl, pH 7.4 (Sigma-Aldrich). 2 μl of this DNA extract was 
 16 
used per PCR reaction, and 1 μl of PCR product was diluted in 9 μl of formamide for 
high-resolution fragment analysis (DNA Analysis Facility at Yale University). 
Chromatograms were analyzed by GeneMapper software (Applied Biosystems) to 
identify insertion-deletion mutations. F0 founders are mosaic and some were found to 
have multiple germline mutations. F0 were backcrossed to wild-type fish and F1 
heterozygotes carrying mutations of interest in cntnap2a and cntnap2b were crossed to 
generate double heterozygotes (F2). Germline frequencies for each mutation were the 
following: cntnap2a: Δ121, Δ25: 17%; cntnap2b, Exon 2: Δ7, 63%; Exon 4: 31ins, 29%.  
Genotyping was performed using the following sets of PCR primers: 
cntnap2a, Exon 3, 485 bp: 5’ ACCCTTAAAATTGATAAAAGAACACG 3’ / 
5’ GCAGAAAAGGGGCTAAATTAAAA 3’ 
cntnap2b, Exon 2, 388 bp: 5’ TGCGATGTGTATCATATGTTCTTTT 3’ / 
5’ AAAAAGGTAGCTCAAACTGTAATTG 3’ 
cntnap2b, Exon 4, 404 bp: 5’ CCTTGCATAATTAAACTGAAATGCT 3’ / 
5’ TGGTTCTCTTGTTTCATTTGGTC 3’ 
 
Sequences of full-length cntnap2a and cntnap2b 
 Because annotations of cntnap2a and cntnap2b were incomplete at the 5’ end in 
earlier assemblies of the zebrafish genome, Rapid Amplification of cDNA Ends (5’ 
RACE) was performed using the GeneRacer kit (Life Technologies) following the 
manufacturer’s protocol. First, total RNA was isolated from 24, 48, 72 and 120 hpf 
embryos using TRIzol reagent (Life Technologies) and purified using the RNeasy Mini 
Kit (Qiagen). mRNA was isolated from pooled RNA from these four stages using 
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oligo(dT) primer (Invitrogen) fixed to streptavidin magnetic beads (New England 
Biolabs).  The following gene-specific 5’ RACE reverse primers were used: 
cntnap2a:  5’ CCCAGATGTTGCCATCTTGATGGTATGG 3’ 
cntnap2b:  5’ CAGTCCAGTGGGATGAAACGCACATA 3’ 
 After determining the sequence of the first exon of each gene by 5’RACE, full-
length cntnap2a (BamHI-XhoI) and cntnap2b (BstBI-XbaI) were cloned into pCS2+ (+/- 
3’HA tags) by RT-PCR using pooled cDNA from 24, 48, 72, and 120 hpf embryos (or 72 
and 120 hpf only). The full-length sequences of both genes will be submitted to 
Ensembl. The current annotation of cntnap2a in GRCz10 does not include the 
sequence of the first exon as determined by 5’RACE in our experiments. 
 To assess for alternate start sites of either transcript, 5’RACE was performed 
using the following gene-specific reverse primers: 
cntnap2a: 5’ GTGGAGGTGCTGAAGCTGAAGGTCA 3’ 
cntnap2a, Nested: 5’ CTGCTTCAAAGAAACCACCAACATC 3’ 
cntnap2a, 2nd Nested: 5’ CATTTGCCACCATTACGACAATACA 3’  
cntnap2b #1: 5’ GGTGTGTTGAAAGAAGCAGCGTTCC 3’ 
cntnap2b #1, Nested: 5’ CAACCACAACCTGACTCACAGGTAA 3’ 
cntnap2b #1, 2nd Nested: 5’ GTGCAGTTGCGTTCAATACCACA 3’ 
cntnap2b #2: 5’ CACCGCAGACTCGCCTTCCTTTAGT 3’ 
cntnap2b #2, Nested: 5’ TGCAGTCGCATGAGTATCCATTGTA 3’ 
cntnap2b #2, 2nd Nested: 5’ ATAACTGCTACAGTGGCCCGAACAT 3’ 
 For cntnap2a, one specific 5’RACE product of ~3kb was identified corresponding 
to the full-length transcript with the same start site (data not shown). No other specific 
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5’RACE products were identified. For cntnap2b, mispriming of the GeneRacer 5’ Nested 
primer within cntnap2b yielded nonspecific products. These results indicated that there 
were no shorter transcripts or alternate start sites identified.  
Regarding current annotations of zebrafish cntnap2, the full-length sequence of 
cntnap2a that we cloned by RT-PCR is not annotated completely in GRCz10, in that it 
does not include the sequence of the first exon as determined by 5’RACE in our 
experiments. In the Ensembl genome browser (GRCz10), there is one gene on 
chromosome 24 corresponding to cntnap2a (ENSDARG00000058969) that is predicted 
to have 2 transcripts: ENSDART00000154039 and ENSDART00000155843, both of 
which have incomplete 5’ coding sequences. The function of ENSDART00000155843, 
which is predicted to yield a product of 190 aa, is unknown and requires further 
investigation. In Ensembl (GRCz10), there is one gene on chromosome 2 
corresponding to cntnap2b (ENSDARG00000074558) that is predicted to have 2 
transcripts: ENSDART00000108900 (full-length, 1315 aa) and ENSDART00000155125, 
which is predicted to encode a protein of 566 aa. Our 5’RACE and western blotting 
experiments would be expected to detect the longer transcript of cntnap2a 
(ENSDART00000154039) and both transcripts of cntnap2b (ENSDART00000108900; 
ENSDART00000155125). No other shorter proteins were detected by western blot 
using our custom antibody (data not shown), indicating our ZFN-induced mutants 
containing indels in exons 2 to 4 would be expected to disrupt Cntnap2a and Cntnap2b 
function. 
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In situ hybridization 
In situ hybridization was performed according to the method previously described 
(Thisse et al., 1993). After staining, embryos were fixed in 4% PFA, washed in PBST 
and sequentially dehydrated in methanol. Embryos were cleared in benzyl 
benzoate/benzyl alcohol for imaging. Fluorescent in situ hybridization was adapted from 
the protocol described in (Julich et al., 2005). Probes were detected with anti-
Digoxigenin-POD, Fab fragments (Roche, 1:1000) and TSA Plus Cyanine 3 System 
(Perkin Elmer). Primary antibody to acetylated tubulin (mouse monoclonal IgG2b, 
#T7451, Sigma-Aldrich) was used at 1:500. Following staining, embryos were mounted 
for confocal imaging in low melting point agarose (0.8-1%).  
Probes for cntnap2a and cntnap2b were amplified from a pooled sample of cDNA 
from 0, 6, 24, 48, and 120 hpf embryos and cloned into pBluescript (BamHI-XhoI). 
Sequences of PCR primer pairs for the cntnap2a and cntnap2b probes are:  
cntnap2a, 520 bp: 5’ GCATAATCCACAACCTTCCAGTC 3’ /  
5’ TTCCCCTGGTGCGAGACGGACAC 3’ 
cntnap2b, 1108 bp: 5’ GTGCTGGCAGCGGATTTTGGTG 3’ / 
5' CCTCCACCCCTCCAGGCATGAGC 3' 
In addition, a second probe (517 bp) located closer to the 3’ end of cntnap2b was 
found to have the same expression pattern as the longer probe (data not shown). 
Primers for this probe are:  
5’ CGAGTCTGCGGTGCTGGGCATTGTG 3’ /  
5’ GACTCCCTGTATGGAGGCAGTGGAC 3’ 
Plasmids for transcribing the in situ probes for gad1b, vglut2a, glyt2, and neurod1 
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were gifts from Brent Bill from the laboratory of Daniel Geschwind. The primer pairs for 
generating these probes are: 
gad1b: 5’ CGTCTTCTGCACCTTCTTCCT 3’ / 
5’  AGATGTGAACAGCACGAGCC 3’ 
vglut2a: 5’ AGGGAGCCTGCTGGTTTTAG 3’ /  
5’ CTGCAGGTCCTAGCAGCTTAG 3’ 
 
glyt2: 5’ TTGTGACGTGTACGAACAGC 3’ /  
5’ CAAGTGGGTCGATCATGTTCT 3’  
 
neurod1: 5’ GCAGGATGCCTCCAACTGA 3’ /  
5’ GTGACCGCAACGTAGAAGC 3’  
 
The plasmid for transcribing tag1 was a gift from the laboratory of Gavin Wright 
(Thisse et al., 2008), and th1 was a gift from the laboratory of Pertti Panula (Chen et al., 
2009). 
Antisense digoxigenin (DIG)-labeled RNA probes were synthesized for 3 hours at 
37°C in 20 μl reactions containing the following: 2 μl 10X transcription buffer (Roche), 2 
μl 10X DIG RNA labeling mix (Roche), 1 μl 100 mM DTT (Roche), 1 μl RNaseOUT 
recombinant ribonuclease inhibitor (Invitrogen), 2 μl RNA polymerase (T7, SP6, or T3) 
(Roche), and 12 μl of linearized purified plasmid. Following probe synthesis, 2 μl of 
DNase I (amplification grade) (Invitrogen) was added to each sample for 30 minutes at 
37°C. Probes were purified using the RNeasy Mini Kit (Qiagen). 24-48 hpf embryos 
were fixed in 4% paraformaldehyde (PFA) overnight at 4°C, washed in PBST (PBS + 
0.1% Tween 20), dehydrated sequentially in methanol/PBST, and stored at -20°C at 
least overnight. 
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Immunohistochemistry 
Whole mount antibody staining of dissected embryos was performed as 
previously described, with some modifications (Wilson et al., 1990). In brief, embryos 
were fixed in 4% sucrose/4% PFA at room temperature for 1 h per 24 h of development. 
Following fixation, embryos were washed in PBS and dissected according to the 
method previously described (Wilson et al., 1990), then dehydrated sequentially in 
methanol-PBT (PBS + 0.5% Triton X-100) and stored in methanol at -20°C at least 
overnight. Embryos were rehydrated sequentially, washed in PBT, digested with 
proteinase K (10 μg/ml for 10 minutes (28 hpf) or 20 minutes (48 hpf); 20-40 μg/ml for 
72, 96, and 120 hpf, respectively for 20 minutes), and post-fixed in 4% sucrose/4% PFA 
for 20 minutes at room temperature. Embryos were blocked for at least 1 h at room 
temperature in 10% normal goat serum/1% DMSO/0.5% Triton X-100 in PBS, and 
incubated in primary antibodies overnight at 4°C. Embryos were washed 4-6 times for at 
least 30 minutes in PBT at room temperature and incubated in secondary antibodies for 
2 h at room temperature or overnight at 4°C. Embryos were washed 4-6 times for at 
least 30 minutes at room temperature or overnight at 4°C in PBT and mounted for 
imaging in low melt agarose (0.8-1%). Tubes containing embryos were rotated at each 
step. Immunostaining to visualize forebrain commissure formation (Figure S1K-K’) was 
performed in undissected embryos according to the method previously described 
(Barresi et al., 2005). The following primary antibodies were used: acetylated-Tubulin 
(mouse monoclonal IgG2b, #T7451, Sigma-Aldrich, RRID:AB_609894, 1:500 or 1:800); 
SV2 (mouse monoclonal IgG1, DSHB, 1:500); GABA (rabbit polyclonal, #A2052, Sigma-
Aldrich, RRID:AB_477652, 1:500); GFP (rat monoclonal IgG2a, #04404-84, Nacalai 
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Tesque, Inc., RRID:AB_10013361, 1:1000); RFP (rabbit polyclonal, #600-401-379, 
Rockland, RRID:AB_2209751, 1:1000); GFAP (rabbit polyclonal, #Z0334, DAKO, 
RRID:AB_10013382, 1:400); Phospho-Histone H3 (Ser10) (rabbit polyclonal, #9701, 
Cell Signaling, RRID:AB_331535, 1:200). The following Alexa Flour secondary 
antibodies were used (Life Technologies, 1:200): 488 or 633 goat anti-mouse IgG2b; 
568 goat anti-mouse IgG1; 488 or 546 goat anti-rabbit IgG (H+L); 488 goat anti-rat IgG 
(H+L). 
 
TUNEL 
 TUNEL labeling to detect apoptotic cells was performed using the ApopTag kit 
(Chemicon International) with modifications to the standard protocol. 28 hpf embryos 
(undissected) were fixed in 4% PFA overnight at 4°C, washed in PBST (PBS + 0.1% 
Tween 20), sequentially dehydrated in methanol-PBST, and stored in methanol at -20°C 
at least overnight. Embryos were sequentially rehydrated and washed in PBST, then 
digested with proteinase K (10 μg/ml) for 18 minutes at room temperature and re-fixed 
in 4% PFA for 20 minutes at room temperature. Next, embryos were washed in PBST 
and incubated for 10 minutes in 2:1 ethanol:acetone at -20°C, washed again and 
incubated in equilibration buffer for 1 hour at room temperature. Embryos were rotated 
during all room temperature incubations. The following ratio of ApopTag enzyme and 
buffer was used: 12 μl TdT enzyme, 24 μl reaction buffer, and 1 μl of 10% Triton X-100. 
18 μl of the reaction mix was added per tube containing 5-10 embryos overnight at 
37°C. After the labeling reaction, embryos were washed in PBST, blocked, and 
developed as in the in situ hybridization protocol (Xu et al., 1994). 
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Imaging and data processing 
 Whole-mount immunostained embryos were imaged by confocal microscopy 
(Leica Systems, UCL Research Department of Cell and Developmental Biology; Zeiss 
and Leica Systems, Yale Center for Cellular and Molecular Imaging). Maximum intensity 
projections are shown for all confocal images, which were processed using Volocity 
(Improvision), Fiji (Schindelin et al., 2012), or Imaris (Bitplane). Dissected 24 hpf 
embryos were mounted laterally and imaged at 25X (0.8W) (Z-distance ≈ 74 μm). 
Dissected 48-120 hpf embryos were mounted at various orientations and imaged at 25X 
(0.95W) using Z-stacks ranging from ~150-250 μm. Embryos stained by fluorescent in 
situ hybridization were analyzed at 20X (0.8W) or 25X (0.95W). Figures were 
assembled using Illustrator (CC, Adobe). 
To quantify GABA+ neurons at 28 hpf, dissected embryos were mounted laterally 
and imaged at 25X (0.8W). Z-stacks (80-110 μm, average=93 μm) started at the first 
appearance of the telencephalic neuropil and ended immediately past the midline at the 
point where GABA+ cells could no longer be visualized. Three blinded raters performed 
GABA cell counts on Z-stack images using the Cell Counter plug-in for Fiji 
(http://rsb.info.nih.gov/ij/plugins/cell-counter.html). This plug-in allows raters to manually 
mark individual cells in a z-stack and counts the cells as they marked. To quantify 
dlx5a/6a:GFP+ neurons in the forebrains of Tg(dlx6a-1.4kbdlx5a/dlx6a:GFP) larvae at 
96 hpf, with or without early exposure to biochanin A (0.1 μM), dissected embryos were 
mounted laterally or ventrally and imaged at 25X (0.95W). Z-stacks (WT: lateral=300-
340μm, average=323μm; ventral=250-290μm, average=273μm; cntnap2ab: 
lateral=260-330μm, average=302μm; ventral=240-300μm, average=267μm) were 
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obtained of the whole brain, beginning and ending with the first and last appearance of 
the axon scaffold, respectively. dlx5a/6a:GFP+ neurons were counted in the forebrains 
of wild-type and mutant larvae in lateral and ventral images manually and blindly by a 
single rater using the Cell Counter plug-in for Fiji.  
To measure head size, lateral images of live 30 hpf embryos or 96 hpf larvae 
anesthetized with MS-222 were obtained using a dissecting microscope. A single 
blinded rater traced the perimeters of the head using the otic vesicle as a posterior 
boundary, eye, and yolk using Fiji (Figures S1N-O and S1N’-O’). To measure brain size, 
maximum intensity projections of lateral and ventral confocal Z-stacks (WT: lateral=300-
340μm, average=318μm; ventral=250-280μm, average=271μm; cntnap2ab: 
lateral=270-330μm, average=297μm; ventral=240-300μm, average=265 μm) of 96 hpf 
dissected whole brains stained with anti-acetylated tubulin were imaged at 25X (0.95W). 
Using Fiji, a single blinded rater traced the perimeter of the brain with the midbrain-
hindbrain boundary as the posterior boundary (Figures S1P-Q and S1P’-Q’). 
To analyze forebrain commissure formation, embryos were cleared in 75% 
glycerol, mounted between two cover slips, and imaged at 40X (1.2W) in Z-stacks of 
~14 μm. Three blinded raters assessed the degree of forebrain commissure formation in 
maximum intensity projection images based on a previously defined scale (Barresi et 
al., 2005). Whole mount in situ images were analyzed using Zeiss Axioimager M1 and 
Discovery microscopes and photographed with a Zeiss Axiocam digital camera. Images 
were processed with Zeiss AxioVision 3.0.6. 
Imaris 7.7.2 software (Bitplane) was used to quantify dlx5a/6a:GFP+ neurons 
and vglut:DsRed and acetylated tubulin surface area by brain region in Tg(dlx6a-
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1.4kbdlx5a/dlx6a:GFP::vglut:DsRed) larvae at 4 dpf. First, a surface was generated to 
demarcate each region. To quantify markers in lateral images, the surface was traced 
from the lateral edge of the brain to the brain mid-line, which demarcated the region 
where the staining was strongest. The following mounting orientations were used to 
quantify the respective regions: forebrain and hypothalamus: ventral and lateral; optic 
tectum and cerebellum: dorsal and lateral. dlx5a/6a:GFP+ cells were counted using an 
estimated XY diameter = 6 µm and filtered by quality with the following cutoffs: forebrain 
and hypothalamus, 23; cerebellum, 15; optic tectum, 10. vglut:DsRed and acetylated 
tubulin surface area were measured using a surface area detail level = 1.000 µm and 
the smooth function with the following absolute intensity cutoffs for glutamate (vglut) and 
tubulin (AcTub): forebrain: vglut, 40 and AcTub, 25; hypothalamus: vglut, 40 (ventral 
images)/30 (lateral images) and AcTub, 25; cerebellum: vglut, 30 (dorsal images)/25 
(lateral images) and AcTub, 25; optic tectum, vglut, 25 and AcTub, 15. Cell number and 
surface area values were normalized to the wild-type average for each orientation. 
Images were analyzed blindly by a single rater. 
 
 RT-PCR 
 Total RNA was extracted from 25 wild-type, cntnap2aΔ121/Δ121cntnap2b31i/31i or 
cntnap2aΔ121/Δ25cntnap2b31i/Δ7 larvae at 5 dpf using TRIzol reagent (Life Technologies) 
and purified using the RNeasy Mini Kit (Qiagen). First strand cDNA synthesis was 
performed according to the manufacturer’s recommendations using SuperScript II or III 
First-Strand Synthesis System (Invitrogen). Limited-cycle PCR to amplify exons 1 to 6 of 
cntnap2a and cntnap2b, which is the region containing ZFN-induced indel mutations, 
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was performed using the following primer pairs: 
cntnap2a, 808 bp: 5’ ATTTTAAGCCACATCAGCATCTCTC 3’ /  
5’ TTCTCCTGTAGCGCTCAATTACTAC 3’ 
cntnap2b, 718 bp: 5’ TATGGTGTGTTTATGTGAAGCTCAG 3’ /  
5’ TGAATGGAGCCGTACTGATTACT 3’ 
  Genomic DNA lengths for these primer pairs are: cntnap2a: 356,671 bp; 
cntnap2b: 40,857 bp. Sanger-sequencing of cntnap2a and cntnap2b RT-PCR products 
from wild-type cDNA produced clear sequences with no evidence of exon-skipping 
involving exons 1-6. Sanger sequencing of RT-PCR products from cDNA from 
cntnap2aΔ121/Δ25cntnap2b31i/Δ7 transheterozygotes indicated that both mutant alleles 
were being transcribed. To resolve the sequences of these transcripts and to assess for 
alternatively spliced transcripts in this region in cntnap2aΔ121/Δ121cntnap2b31i/31i and 
cntnap2aΔ121/Δ25cntnap2b31i/Δ7 larvae, RT-PCR products from these mutants were 
cloned using either TOPO-TA or Zero Blunt PCR TOPO Cloning Kit (Invitrogen) and 
plasmid DNA was isolated (QIAprep Miniprep kit, Qiagen) from ~10 colonies per PCR 
product (total of ~40 colonies) and Sanger-sequenced individually using M13F/R 
primers (Keck Biotechnology Resource Laboratory, Yale University). 
 
Generation of antibodies against zebrafish Cntnap2a and Cntnap2b 
Custom antibody recognizing zebrafish Cntnap2a and Cntnap2b (YZ3970) was 
generated by YenZym Antibodies, LLC, using a peptide antigen corresponding to amino 
acids 867 to 886 of Cntnap2a: TPLNDDQWHRVSAERNTKEAC-amide. This region is 
90% identical between Cntnap2a and Cntnap2b and occurs within the third Laminin-G 
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domain of both proteins. To verify that this antibody recognized both Cntnap2 proteins, 
HA-tagged full-length Cntnap2a and Cntnap2b were cloned into pCS2+ and transfected 
into HEK cells using lipofectamine 2000 reagent (Invitrogen). Total protein was isolated 
from transfected HEK cells and analyzed by SDS-PAGE and western blotting. YZ3970 
was found to recognize both overexpressed proteins by western blot (data not shown). 
 
Western blot 
To analyze Cntnap2a and Cntnap2b expression, total protein was isolated from 
the heads of 72 hpf larvae with the following genotypes: wild-type, cntnap2ab double 
homozygotes, single homozygotes, and double heterozygotes from both mutant lines 
(cntnap2aΔ121/Δ121cntnap2b31i/31i and cntnap2aΔ25/Δ25cntnap2bΔ7/Δ7). 10 ml of lysis buffer 
was prepared fresh containing 1 ml of 10X Cell Lysis Buffer (#9803, Cell Signaling), 100 
μl of 0.1 M PMSF, 1 complete protease inhibitor cocktail tablet (Roche), and 9 ml 
distilled water. Protein was isolated using 150 μl of lysis buffer per 62 decapitated 72 
hpf heads. Samples were homogenized on ice by mechanical grinding, then rotated at 
4°C for 20 minutes and immediately stored at -80°C at least overnight. Upon thawing, 
samples were centrifuged at 13,000 rpm for 3 minutes to pellet insoluble material. 20 μl 
of the supernatant from each sample was diluted 1:1 in 2X loading buffer (prepared from 
4X NuPAGE LDS Sample Buffer, Invitrogen) with 20% β-mercaptoethanol, and boiled 
for 2 minutes at 95°C. 30-34 μl of each sample was loaded per lane and analyzed by 
SDS-PAGE using 7.5% mini-PROTEAN TGX precast gels (Bio-Rad). The 
polyacrylamide gel was transferred to a PVDF membrane using a wet transfer system 
(Bio-Rad). Primary antibodies used for western blotting included: Affinity-purified custom 
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antibody directed against Cntnap2A and Cntnap2B (YenZym, YZ3970, 1:500); β-actin 
(mouse monoclonal, #A1978, Sigma-Aldrich, RRID:AB_476692,1:5000). After probing 
with primary antibody, blots were stripped with Restore Western Blot Stripping Buffer 
(Thermo Scientific) and reprobed with antibody to β-actin. Secondary antibodies 
included peroxidase-conjugated AffiniPure donkey anti-rabbit IgG (H+L) and 
peroxidase-conjugated AffiniPure donkey anti-mouse IgG (H+L) (Jackson 
ImmuoResearch Laboratories, Inc., 1:10:000).  
 
Locomotor activity assay 
The behavioral assay was conducted as described previously (Prober et al., 
2006; Rihel et al., 2010). In brief, individual 4 dpf larvae were placed in a 96-well plate 
(7701-1651; Whatman, Clifton, NJ) containing 650 μl of standard embryo water (0.3 g/L 
Instant Ocean, 1 mg/L methylene blue, pH 7.0). The 96-well plate was maintained at a 
constant temperature (28.5°C) and exposed to a 14h:10h white light:dark schedule with 
constant infrared illumination within a custom-modified Zebrabox (Viewpoint, 
LifeSciences) (Figure 2A). Larval activity was monitored for 60-72 hours using an 
automated video tracking system (Zebrabox and Videotrack software; Viewpoint Life 
Sciences, Montreal, Quebec, Canada). Larval movement was recorded using 
Videotrack quantization mode. The Videotrack detection parameters were empirically 
defined for clean detection of larval movement with minimal noise. To control for 
differences in genetic background, all tracking experiments were performed blindly on 
the progeny of double heterozygous cntnap2a+/-2b+/- fish. After tracking, genomic DNA 
was isolated from individual larvae and genotyping was done by PCR and high-
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resolution fragment analysis (DNA Analysis Facility at Yale University). 
 
Pentylenetetrazol activity assay 
 For the dose-response experiments, individual cntnap2aΔ121/Δ121cntnap2b31i/31i or 
wild-type larvae at 4 or 6 dpf were pipetted into the wells of a 96-well plate containing 
650 μl of standard embryo water. As above, the plate was placed in a custom-modified 
Zebrabox. Larval movement was recorded by the Videotrack system for 1 h before and 
after the addition of PTZ or water. Videotrack detection parameters were determined as 
above. PTZ was diluted in sterile distilled water and either PTZ or water alone was 
pipetted directly into each well to yield the following PTZ final concentrations: 2.5, 5, 7.5, 
10, and 15 mM. At 6 dpf, the total number of larvae tested per concentration of PTZ 
was: 2.5, 5, 7.5, 10 mM, n=42-48; 15 mM, n=24; water only, n=68. At 4 dpf: 2.5, 7.5, 15 
mM, n=10-12; 5, 10 mM, water only, n=34. Data were analyzed by normalizing the post-
PTZ activity of each fish to itself prior to the addition of PTZ or water. For blinded 
experiments, the progeny of incrosses of cntnap2aΔ25/+cntnap2bΔ7/+ fish at 4 dpf (n=268) 
were pipetted individually into the wells of a 96-well plate. Sterile water or PTZ (final 
concentration=10 mM) was pipetted directly into the wells of one-half of the same 96-
well plate. 10 mM PTZ was selected because this dose was found to illicit the largest 
differential response in wild-type versus mutant fish at 6 dpf (Figure S3C). Genomic 
DNA isolation and genotyping were performed after each experiment. 
 
Chemical screens 
Selection of psychoactive agents was based on the following criteria (Figure 3A): 
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i) behavioral phenotype of wild-type fish plus drug strongly correlates with the 
phenotype of cntnap2aΔ25/Δ25cntnap2bΔ7/Δ7 mutants (L-701,324 and MK-801); ii) 
behavioral phenotype of wild-type fish plus drug strongly anti-correlates with the mutant 
phenotype (9 drugs); iii) GABAergic mechanism (zolpidem, diazepam); iv) clinical use in 
treating aggression or irritability in ASD (risperidone). Three doses of each drug were 
selected based on previous studies of the dose range that induces behavioral effects 
and minimizes toxicity in larval zebrafish (Rihel et al., 2010). All agents were dissolved 
in DMSO with the exception of baclofen, which was dissolved in water. DMSO alone at 
<0.2% has been shown not to affect behavior (Rihel et al., 2010). Each drug 
concentration was tested on 10-12 cntnap2aΔ121/Δ121cntnap2b31i/31i or wild-type larvae, 
with 10-12 control larvae per 96-well plate. Stock solutions of each compound dissolved 
in DMSO or DMSO alone were pipetted directly into the wells of a 96-well plate 
containing 650 μL of standard embryo water.  
Final concentrations of each drug tested in wild-type and 
cntnap2aΔ121/Δ121cntnap2b31i/31i larvae are shown in the following table: 
Compound Catalog # Company Dose Range 
(μM) 
Amantadine 
hydrochloride 
A1260 Sigma 3, 10, 30 
(±)-Baclofen B5399 Sigma 0.1, 1, 10 
β-estradiol 17-
cypionate 
E8004 Sigma 0.1, 1, 10, 30 
Biochanin A D2016 Sigma 0.1, 1, 10 
Chlorzoxazone C4397 Sigma 1, 10, 30 
Clonidine hydrochloride C7897 Sigma 1, 10, 30 
CSG-12066 maleate 
salt 
C106 Sigma 0.1, 1, 10 
Diazepam C-IV D0899 Sigma 0.1, 1, 10 
β-Estradiol E1024 Sigma 1, 10, 30 
L-701,324 L0258 Sigma 3, 10, 30 
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(-)-MK-801 hydrogen 
maleate 
M108 Sigma 3, 10, 30 
Risperidone R3475 LKT 
Laboratories 
0.001, 0.01, 1, 
10, 30 
Ticlopidine 
hydrochloride 
T6654 Sigma 1, 10, 30 
Zolpidem N/A Gift from  
David Sugden 
1, 10, 20 
 
Amantadine was identified as anti-correlating by using a more extensive dataset 
of 6,000 compounds, which was previously filtered to yield the list of 550 compounds 
(Rihel et al., 2010). For blinded experiments, the progeny of incrosses of 
cntnap2aΔ25/+cntnap2bΔ7/+ fish (n=560, 2 independent experiments) were pipetted 
individually into the wells of a 96-well plate. DMSO or biochanin A (final 
concentration=0.1-1μM) was pipetted directly into the wells of one-half of the same 96-
well plate. Genomic DNA was isolated and fish were genotyped after each experiment. 
 
Hierarchical clustering 
 Behavioral phenotypes of wild-type fish exposed to a panel of 550 psychoactive 
agents from 4 to 7 dpf were ascertained as previously described (Rihel et al., 2010). To 
compare the behavioral fingerprints of wild-type larvae exposed to each drug and the 
cntnap2aΔ25/Δ25cntnap2bΔ7/Δ7 mutant behavioral fingerprint, hierarchical clustering 
analysis was performed as in (Rihel et al., 2010). 
 
Correlation analysis 
 Correlation analysis was performed in Matlab (R2014a; The Mathworks, Inc.) as 
previously described (Rihel et al., 2010). 
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Rank correlation analysis 
To conduct rank correlation analysis of NMDA antagonists and estrogenic 
analogs, compounds were assigned to pharmacological classes as described (Rihel et 
al., 2010). Estrogenic agents were additionally annotated by hand blind to rank using 
PubChem (pubchem.ncbi.nlm.nih.gov/). Assays of bioactivity in a set of in vitro estrogen 
receptor-α tests deposited at PubChem were included. Insecticides were the only class 
of compounds that were excluded due to their strong effects on sodium channels. Rank 
correlation analysis was performed as described using the Kolmogorov-Smirnov statistic 
to assess significance (Rihel et al., 2010). Rank-sorting of anti-correlating drugs 
revealed that estrogenic compounds are significantly enriched in this dataset. 
Specifically, 25 compounds in our dataset of 550 were identified as estrogenic. Four of 
the top 10 anti-correlating agents are estrogenic. We created 10,000 randomly 
permuted datasets and found similar or better enrichment in only three permuted 
datasets, giving a p-value estimate of 3/10,000 or 0.0003. Using both strict and relaxed 
criteria for defining estrogenic agents demonstrated enrichment of these agents in the 
top ranks. 
 
Principal components analysis 
Data were aggregated for 18 rest-wake parameters (sleep, rest bouts, average 
total activity, average waking activity; each of these parameters was determined for 
nights 5 and 6 and days 5 and 6; and night and day average waking activity) and each 
drug-dose combination. For the differential response PCA, each data point was defined 
as the Z-score of the response of wild-type or cntnap2aΔ121/Δ121cntnap2b31i/31i mutant 
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larvae to each drug compared to their baseline (DMSO alone). For the PCA to identify 
drugs that reverse the behavioral fingerprint of mutants, each data point was defined as 
the Z-score of the response of cntnap2aΔ121/Δ121cntnap2b31i/31i mutant larvae exposed to 
each drug compared to the behavioral fingerprint of untreated wild-type larvae. 
Hierarchical clustering was conducted in Matlab (R2014a), with the statistics and 
bioinformatics toolboxes. PCA was performed according the method described in 
(Woods et al., 2014). 
 
Long-term Exposure to Biochanin A 
 To assess the extent to which exposure to biochanin A affects GABAergic cell 
numbers, biochanin A dissolved in DMSO or DMSO alone was added to petri dishes 
containing Tg(dlx6a-1.4kbdlx5a/dlx6a:GFP) wild-type or cntnap2aΔ121/Δ121cntnap2b31i/31i 
embryos at 30 hpf (n=6-11/dish) and embryos were raised in the presence of either 
biochanin A (final concentration=0.1 μM) or DMSO. At 4 dpf, larvae were fixed, 
dissected, immunostained and imaged by confocal microscopy, as described above. 
dlx5a/6a:GFP+ cells in the forebrain were counted manually as described.  
To determine the extent to which chronic exposure to biochanin A affects 
nighttime hyperactivity, wild-type or cntnap2aΔ121/Δ121cntnap2b31i/31i embryos were 
exposed to biochanin A (1 μM) dissolved in DMSO or DMSO alone at 24 hpf 
(n=50/dish). Biochanin A (1 μM) or DMSO was added daily. At 4 dpf, each larva was 
pipetted into fresh embryo water, allowed to swim for 30 seconds, and placed in a 96-
well plate with fresh embryo water. The locomotor activity of wild-type or mutant 
embryos was tracked for 48 hours using the automated tracking assay described above. 
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To test the effect of biochanin A exposure on PTZ-induced seizures, wild-type or 
cntnap2aΔ121/Δ121cntnap2b31i/31i embryos were exposed to biochanin A (1 μM) dissolved 
in DMSO or DMSO alone at 24 hpf (n=50/dish) and biochanin A (1 μM) or DMSO was 
added daily. At 4 dpf, larvae were plated in a 96-well plate containing either biochanin A 
or DMSO. Larvae were allowed to habituate for 15 minutes and baseline locomotor 
activity was tracked for two hours, after which 10 mM PTZ was added to each well and 
locomotor activity was tracked for two hours using the automated assay described 
above. 
 
qPCR 
To assess the effect of biochanin A exposure on estrogen target genes, groups 
of ~35 wild-type larvae were exposed to biochanin A (1 μM, 10 μM) or DMSO overnight 
from 4 to 5 dpf. Biochanin A (1 μM, 10 μM) and DMSO exposure were conducted in 
duplicate samples. Total RNA was isolated using TRIzol reagent (Life Technologies) 
and purified using the RNeasy Mini Kit (Qiagen). cDNA was synthesized using 1000 ng 
of total RNA and the SuperScript III First-Strand Synthesis System (Invitrogen). 
Expression of the following three genes was analyzed by qPCR: vitellogenin 1 (vtg1); 
estrogen receptor 1 (esr1); cytochrome P450, family 19, subfamily A, polypeptide 1 
(aromatase B, cyp19a1b). These genes were selected because they were found to be 
upregulated in response to 17β-estradiol in zebrafish embryos (Hao et al., 2013). We 
selected cyp19a1b because it is expressed in the brain during early development (Hao 
et al., 2013). cyp19a1b primer sequences were obtained from (Hao et al., 2013). Primer 
sequences for vtg1 and esr1 are shown below: 
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vtg1, 106 bp: 5’ GAGATGCAAGAGGCTGGAG 3’ /  
5’ GGCTCAGATCTTTAGACTTTGTCAC 3’ 
esr1, 122 bp: 5’ TTACGGAGTCTGGTCGTGTG 3’ /  
5’ AGCTCTTTCGACGGTTTCTG 3’ 
 
Other larval behavioral assays 
 Acoustic startle, habituation, and PPI were analyzed in 
cntnap2aΔ121/Δ121cntnap2b31i/31i (n≈70), cntnap2aΔ121/+cntnap2b31/+ (n≈70), and wild-type 
(n≈50) larvae at 5 to 7 dpf by raters blind to genotype, according to the method 
previously described (Wolman et al., 2011). After the initial analysis indicated that there 
may be a difference in the LLC response rate of mutants, the progeny of incrosses of 
cntnap2aΔ121/+cntnap2b31i/+ fish were blindly tested for LLC responsiveness and 
genotyped after the experiment (total n=318; cntnap2aΔ121/Δ121cntnap2b31i/31i, n=14; 
cntnap2aΔ121/+cntnap2b31i/+, n=92; wild-type, n=24). The optokinetic response assay was 
performed on cntnap2aΔ121/Δ121cntnap2b31i/31i (n=18), cntnap2aΔ121/+cntnap2b31/+ (n=11), 
and wild-type (n=14) larvae at 5 to 7 dpf with different contrast levels of the visual 
stimulus (5-100%). Two independent trials were conducted by raters blind to genotype, 
according to the previously described method (Schoonheim et al., 2010). 
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